1 CLINICAL STUDY PROTO COL  
Title  A Phase 3 E fficacy and Safety Study of Tapi[INVESTIGATOR_402196] 8  
4051 B asel, Switzerland  
Compound Name [CONTACT_279997][INVESTIGATOR_191752] ( DMVT -505) 
Protocol Number DMVT -505-3001 
Indication Plaque Psoriasis  
Development Phase 3 
IND #  104601 
Version/ 
Effective Date:  Original Protocol 25-JANUARY-2019 
Amendment 1 (Version 1.1) 08- MAY-2019 
Amendment 2 (Version 2.0) 08- AUGUST -[ADDRESS_506816] or 
Independent Ethics Committee.  The information is only to be used by [CONTACT_329903] .  You will not disclose any of the 
information to others without written authorization from Dermavant Sciences GmbH, except to the extent 
necessary to obtain informed consent from thos e persons to whom the drug may be administered. 

Tapi[INVESTIGATOR_402197] -505-3001  
Dermavant Sciences GmbH  Clinical Study Protocol – Version 2.0  
Confidential  Page | [ADDRESS_506817] ATEMENT 
Study Title :  A Phase 3 Efficacy and Safety Study of Tapi[INVESTIGATOR_402198]  
 
• I confirm agreement to conduct the study in compliance with the protocol. 
• I acknowledge that I am responsible for overall study conduct.  I agree to personally 
conduct or supervise the described study. 
• I agree to ensure that all associates, colleagues , and employees assisting in the 
conduct of the study are informed about their obligations and comply with the study 
protocol.  Mechanisms are in place to ensure that site staff receives the appropriate information throughout the study. 
 
 
   
Principal Inve stigator Name (Printed)   Signature 
   
[CONTACT_402269][INVESTIGATOR_402197] -505-3001  
Dermavant Sciences GmbH  Clinical Study Protocol – Version 2.0  
Confidential  Page | [ADDRESS_506818] OF ABBREVIATIONS AND DEFINITIONS OF  TERMS  ................................................10  
SYNOPSIS   ....................................................................................................................................12  
SCHEDULE OF ASSESSMENTS  ................................................................................................18  
1. INTRODUCTION  ......................................................................................................21  
1.1. Background Information and Study Rationale ...........................................................21  
1.1.1.  Background Information .............................................................................................21  
1.1.2.  Study Rationale ...........................................................................................................22  
1.2. Rationale for Study Design, Dose, and Control Groups .............................................23  
1.3. Potential Risks and Benefits  .......................................................................................23  
1.3.1.  Risk Assessment  .........................................................................................................23  
[IP_ADDRESS].  Dermatological Adverse Events, Including Skin Irritation or Allergic 
Reaction  ......................................................................................................................23  
[IP_ADDRESS].  Systemic Adverse Events  ...........................................................................................24  
[IP_ADDRESS].  Reproductive and Developmental Toxicity ................................................................24  
1.3.2.  Benefit Assessment  .....................................................................................................25  
1.3.3.  Overall Benefit Risk  ...................................................................................................25  
2. OBJECTIVES AND ENDPOINTS  ............................................................................26  
3. STUDY DESIGN  .......................................................................................................28  
3.1. Overall Design  ............................................................................................................28  
3.2. Treatment Groups and Duration .................................................................................29  
4. STUDY POPULATION  .............................................................................................30  
4.1. Type and Number of Subjects ....................................................................................30  
4.2. Inclusion Criteria  ........................................................................................................30  
4.3. Exclusion Criteria  .......................................................................................................31  
4.4. Lifestyle Restrictions  ..................................................................................................33  
4.5. Screening/Baseline Failures ........................................................................................[ADDRESS_506819] to Follow- Up.......................................................................................................34  
5. STUDY TREATMENT  ..............................................................................................35  
5.1. Study Drug ..................................................................................................................35  
Tapi[INVESTIGATOR_402197] -505-3001  
Dermavant Sciences GmbH  Clinical Study Protocol – Version 2.0  
Confidential  Page | 6 5.1.1.  Description, Packaging, and Labeling ........................................................................35  
5.1.2.  Storage ........................................................................................................................35  
5.1.3.  Handling and Disposal ................................................................................................35  
5.1.4.  Preparation  ..................................................................................................................35  
5.1.5.  Administration of Study Drug ....................................................................................36  
5.2. Randomization/Treatment Assignment ......................................................................37  
5.3. Blinding ......................................................................................................................37  
5.4. Compliance with Study Drug Administration ............................................................38  
5.5. Treatment after the End of the Study ..........................................................................38  
5.6. Prior and Concomitant Therapy ..................................................................................38  
5.6.1.  Permitted Medications and Nondrug Therapi[INVESTIGATOR_014] .........................................................39  
5.6.2.  Prohibited Medications and Nondrug Therapi[INVESTIGATOR_014] ........................................................39  
6. STUDY ASSESSMENTS AND PROCEDURES  ......................................................40  
6.1. Demography, Medical History, and Baseline Characteristics  ....................................40  
6.1.1.  Demographics .............................................................................................................40  
6.1.2.  Medical History  ..........................................................................................................40  
6.1.3.  Baseline Characteristics  ..............................................................................................40  
6.2. Efficacy Assessments  .................................................................................................40  
6.2.1.  Assessments Completed by [CONTACT_10670] ....................................................................40  
[IP_ADDRESS].  Physician Global Assessment .....................................................................................40  
[IP_ADDRESS].  Body Surface Area Affected  .......................................................................................41  
[IP_ADDRESS].  Psoriasis Area and Severity Index  ..............................................................................[ADDRESS_506820] ...........................................................................41  
[IP_ADDRESS].  Dermatology Life Quality Index  ................................................................................41  
[IP_ADDRESS].  36−Item Short Form Survey .......................................................................................41  
[IP_ADDRESS].  Psoriasis Symptom Diary  ...........................................................................................42  
[IP_ADDRESS].  Peak Pruritus- Numeric Rating Scale  ..........................................................................42  
6.2.3.  Optional Clinical Photography ...................................................................................42  
6.3. Safety Assessments  .....................................................................................................42  
6.3.1.  Adverse Events  ...........................................................................................................42  
6.3.2.  Brief Physical Examination  ........................................................................................42  
6.3.3.  Vital Signs  ..................................................................................................................43  
6.3.4.  Clinical Safety Laboratory Assessments  ....................................................................43  
Tapi[INVESTIGATOR_402197] -505-3001  
Dermavant Sciences GmbH  Clinical Study Protocol – Version 2.0  
Confidential  Page | 7 6.3.5.  Local Tolerability Scale  ..............................................................................................44  
6.4. Treatment of Study Drug Overdose ............................................................................45  
6.5. Pharmacokinetics  ........................................................................................................45  
7. TIMING OF PROCEDURES  AND ASSESSMENTS  ..............................................46  
7.1. Visit 1; Screening Period (Day -34 to Day -1) ...........................................................46  
7.2. Visit 2; Baseline (Day  1) ............................................................................................47  
7.3. Double-Blind, Vehicle-Controlled Phase ...................................................................47  
7.3.1.  Visit 3; Week  2 (Day  15 ±2 Days)  .............................................................................47  
7.3.2.  Visit 4; Week  4 (Day  29 ±2 Days)  .............................................................................48  
7.3.3.  Visit 5; Week  8 (Day  57 ±2 Days)  .............................................................................48  
7.3.4.  Visit 6; Week  12 (Day 85 ±2 Days)  ...........................................................................[ADDRESS_506821] at Weeks  6 (Day  43 ±2 Days) and 10 (Day 71 ±2 Days)  ...................50  
7.4. Follow- Up Visit 7; Week  16 (Day 113 ±4 Days)  .......................................................[ADDRESS_506822]  .............................................................................54  
8.2. Classification of Adverse Events ................................................................................54  
8.2.1.  Assigning Severity Rating for Adverse Events ..........................................................54  
[IP_ADDRESS].  Criteria for Determining Averse Event Severity  ........................................................54  
[IP_ADDRESS].  Toxicity Management Criteria  ....................................................................................55  
8.2.2.  Assigning Causal Relationship to Study Drug ...........................................................56  
8.3. Time Period and Frequency for Event Assessment and Follow- Up ...........................56  
8.3.1.  Adverse Event Reporting ............................................................................................56  
8.3.2.  Follow-Up of Adverse Events  ....................................................................................57  
8.4. Reporting Procedures ..................................................................................................57  
8.4.1.  Serious Adverse Event Reporting ...............................................................................57  
8.4.2.  Regulatory Reporting Requirements for Serious Adverse Events .............................57  
8.5. Pregnancy Management and Reporting ......................................................................58  
Tapi[INVESTIGATOR_402197] -505-3001  
Dermavant Sciences GmbH  Clinical Study Protocol – Version 2.0  
Confidential  Page | 8 8.6. Safety Oversight .........................................................................................................58  
9. DATA MANAGEMENT  ...........................................................................................59  
10. STATISTICAL CONSIDERATIONS AND DATA ANALYSES  ............................60  
10.1.  General Considerations ...............................................................................................60  
10.2.  Determination of Sample Size  ....................................................................................60  
10.3.  Analysis Populations ..................................................................................................60  
10.3.1.  Safety  ..........................................................................................................................60  
10.3.2.  Intent- To-Treat  ...........................................................................................................60  
10.3.3.  Per-Protocol ................................................................................................................60  
10.3.4.  Pharmacokinetic  .........................................................................................................60  
10.4.  Planned Analyses ........................................................................................................61  
10.4.1.  Disposition and Demographics ...................................................................................61  
10.4.2.  Efficacy Analyses  .......................................................................................................61  
[IP_ADDRESS].  Primary Endpoint Analyses ........................................................................................61  
[IP_ADDRESS].  Secondary and Exploratory Efficacy Endpoint Analyses ...........................................[ADDRESS_506823]/Independent Ethics Committee Approval ......................64  
11.1.3.  Informed Consent/Assent ...........................................................................................64  
11.1.4.  Confidentiality  ............................................................................................................65  
11.1.5.  Study Files and Retention of Records ........................................................................65  
11.1.6.  Electronic Case Report Forms  ....................................................................................66  
11.1.7.  Drug Accountability ...................................................................................................66  
11.1.8.  Inspections ..................................................................................................................67  
11.1.9.  Protocol Compliance ..................................................................................................67  
11.2.  Sponsor Responsibilities .............................................................................................67  
11.2.1.  Protocol Modifications ...............................................................................................67  
Tapi[INVESTIGATOR_402197] -505-3001  
Dermavant Sciences GmbH  Clinical Study Protocol – Version 2.0  
Confidential  Page | 9 11.2.2.  Study Report and Publications....................................................................................67  
11.2.3.  Posting of Information on Publicly Available Clinical Trial Registers  ......................67  
11.3.  Joint Investigator/Sponsor Responsibilities ................................................................[ADDRESS_506824] O F TABLES  
Table 1:  Schedule of Assessments  ............................................................................................18  
Table 2:  Tapi[INVESTIGATOR_222147]  .....................................................................................35  
Table 3:  Laboratory Tests .........................................................................................................44  
Table 4:  Criteria for Determining the Grade/Severity of Adverse Event Terms Not 
Specified by [CONTACT_191822]  ...................................................[ADDRESS_506825] OF FIGURES  
Figure 1:  Study Schema .............................................................................................................29  
 
 
 
 
 
 
Tapi[INVESTIGATOR_402197] -505-3001  
Dermavant Sciences GmbH  Clinical Study Protocol – Version 2.0  
Confidential  Page | [ADDRESS_506826]  aspartate aminotransferase  
BLQ  below the limit of quantification  
BMI  body mass index  
BSA  body surface area  
%BSA percent of total body surface area  
BUN  blood urea nitrogen 
BWTP  Beijing Wenfeng Tianji Pharmaceuticals  
CBP  child -bearing potential  
CFR  Code of Federal Regulations  
CTCAE  Common Terminology Criteria for Adverse Events  
CV cardiovascular  
D/d day(s) 
Dermavant  Dermavant Sciences GmbH  
DLQI Dermatology Life Quality Index 
ECG  electrocardiogram 
eCRF  electronic case report form  
ET early termination  
FCS Fully Conditional Specification 
F-U follow-up 
[COMPANY_004] GlaxoSmithKline 
HADS  Hospi[INVESTIGATOR_402199] B surface antigen  
HIV  human immunodeficiency virus  
ICF informed consent form  
ICH  International Council for Harmonisation  
Tapi[INVESTIGATOR_402197] -505-3001  
Dermavant Sciences GmbH  Clinical Study Protocol – Version 2.0  
Confidential  Page | [ADDRESS_506827] 
PK Pharmacokinetic (s) 
PND postnatal day  
RBC red blood cell(s)  
PP Per-Protocol  
SAE  serious adverse event  
SAP  Statistical Analysis Plan  
SD standard deviation  
SF-[ADDRESS_506828]  upper limit of normal  
US; [LOCATION_003]  [LOCATION_002] (of America)  
UV ultraviolet  
V visit 
WBC  white blood cell(s)  
WOCBP  women of child -bearing potential 
WHO- DDE  World Health Organization Drug Dictionary Enhanced  
Tapi[INVESTIGATOR_402197] -505-3001  
Dermavant Sciences GmbH  Clinical Study Protocol – Version 2.0  
Confidential  Page | 12 SYNOPSIS  
Name [CONTACT_790]/Company:  
Dermavant Sciences GmbH  
Name [CONTACT_791]:  
DMVT -505 ( tapi[INVESTIGATOR_191753], 1% ) 
Name [CONTACT_3261] :   
Tapi[INVESTIGATOR_222145]:  DMVT -505-3001  Phase : 3 Country:  [LOCATION_002] (US) and Canada 
Title  of Study:  
A Phase  3 Efficacy and Safety Study of Tapi[INVESTIGATOR_402200](s):  
Approximately 50 to 60 s ites in the [LOCATION_002] ( US) and Canada  
Objectives:  
Primary:  
• To evaluate the efficacy of tapi[INVESTIGATOR_191753], 1% compared with vehicle control in adults with plaque 
psoriasis  
Secondary:  
• To further characterize the efficacy of tapi[INVESTIGATOR_191753] , 1% compared with vehicle control over time  
• To describe the effect of tapi[INVESTIGATOR_191753], 1% on psoriasis symptom severity and the associated impact on 
daily activities and attitudes in adults with plaque psoriasis 
• To evaluate the safety and tolerability of tapi[INVESTIGATOR_191753], 1% in adults with plaque psoriasis  
• To characterize the pharmacokinetics ( PK) of tapi[INVESTIGATOR_402201]:  
This is a double -blind, randomized, vehicle -controlled, Phase  3, multicenter study to evaluate the efficacy and 
safety of topi[INVESTIGATOR_222165],  1% compared with vehicle -control cream in adults with plaque psoriasis.    
Following a 34-day screening period, eligible subjects will be randomized at a 2:1 ratio to receive once daily 
treatment with tapi[INVESTIGATOR_191755],  1% or vehicle cream .  Subjects will return to the clin ic at Weeks  2, 4, 8, and 12 for 
efficacy and safety assessments .  Additionally, subjects will be contact[CONTACT_222209] 6 and 10 to assess 
adverse events ( AEs) and concomitant medications, to review study drug administration instructions, and to 
confirm subject’s continued participation in this study. 
Study drug will be dispensed to subjects during the clinic visits and will be administered at home between clinic 
visits as instructed by [CONTACT_8786] .  Subjects will be instructed to apply study drug once daily to all affected 
areas, including newly appearing lesions and lesions /areas  that impr ove during the study.  Subjects will apply 
sufficient study drug to cover completely each lesion with a thin layer of study drug and will record the time of study drug application in a daily diary provided by [CONTACT_3452] .  (Note  that subjects are allowed , but not 
required , to treat fingernails, toenails, palms, soles, and scalp lesions with study drug ; however, efficacy analyses 
will not include assessment of improvement of psoriasis in these areas .) Subjects will be instructed to maintain the  
approximate  dosing time chosen at the beginning of the study for their full study participation.  At the phone 
contacts at Weeks 6, and 10, subjects should be reminded to complete their daily diary and bring it with them to 
the next clinic v isit. 
Study drug application instructions will be reviewed at all post -randomization clinic visits and during any planned 
study phone calls .  On clinic visit days, subjects will be instructed/reminded on how to apply study drug (except 
during the final tre atment/end -of-study visits) .  During the clinic visits, subjects will apply the daily dose of study 
drug while on- site under the supervision of site personnel, after efficacy and safety assessments have been 
completed .  The time of the dose application and  assessments will depend on the time of the clinic visit.   
Therefore, the timing of the clinic visit may lead to a change in the subject’s chosen dosing time , 
Tapi[INVESTIGATOR_402197] -505-3001  
Dermavant Sciences GmbH  Clinical Study Protocol – Version 2.0  
Confidential  Page | [ADDRESS_506829] not to enroll in that 
study, will complete a Follow -up V isit approximately 4  weeks (Week  16 visit) after the end of treatment  in this 
study.   Subjects who with draw from the study before Week  12 w ill complete an Early Termination Visit.    
Number of Subjects: 
Approximately 50 0 subjects ages 1 8 to 75 years will be enrolled in the study as follows :   
• Approximately 50 0 subjects  will be randomized at a 2:1 ratio to receive tapi[INVESTIGATOR_191753], 1% 
(approximately 333 subjects) or vehicle cream (approximately 167 s ubjects)  
Diagnosis and Main Criteria for Inclusion : 
Inclusion Criteria : 
Each subject must meet all of  the following criteria to be eligible to participate in the study: 
1. Male and female subjects ages [ADDRESS_506830] 6 months prior to the study.  
2. Body surface area (BSA) involv ement ≥ 3% and ≤ 20% (the subject’s scalp, palms, fingernails, toenails, 
and soles should be excluded from the percent of total BSA ( %BSA ) calculations ). 
3. A Physician’s Global Assessment ( PGA ) score of  2 (mild),  3 (moderate) or  4 (severe)  at screening and 
baseline (pre- randomization) .  Subjects with mild and severe psoriasis will be limited to approximately 
10% each of the total randomized population; the majority of the enrolled subjects (approximately 80%) 
will have a PGA of 3, signifying moderate disease. 
4. Females of child -bearing potential and male subjects who are engaging in sexual activity that could lead 
to pregnancy must use at least [ADDRESS_506831] expo sure to study drug.   Acceptable contraception methods are:  
• Male partner with vasectomy, OR  
• Male condom AND partner use of 1 of the contraceptive options below:  
− Spermicide  
− Contraceptive subdermal implant that meets effectiveness criteria including a < 1% rate of 
failure per year, as stated in the product label  
− Intrauterine device or intrauterine system that meets effectiveness criteria including a < 1% rate 
of failure per ye ar, as stat ed in the product label  
− Oral contraceptive, either combined or progestogen alone  
− Injectable progestogen  
− Contraceptive vaginal ring  
− Percutaneous contraceptive patches  
NOTE :  Subjects using hormonal contraceptives must have been on a stable dose f or at least [ADDRESS_506832] label .  The Investigator is responsible for ensuring that 
subjects understand how to properly use these methods of contraception .  Non-child -bearing potential is 
defined as premenarchal or pre- menopausal females with a documented bilateral tubal ligation, bilateral 
oophorectomy (removal of the ovaries) or hysterectomy, or hysteroscopic steriliza tion; or 
postmenopausal females defined as a cessation of menses for at least 12 months without an alternative 
medical cause.   In questionable cases a blood sample with simultaneous follicle stimulating hormone 
(FSH) > 40 I U/mL is confirmatory .  Documented  verbal history from the subject is acceptable.   Subjects 
who are abstinent are eligible, but they must agree to use one of the birth control methods listed above if 
they start engaging in sexual activity that could lead to pregnancy during the study.   Female subjects of 
childbearing potential must have a negative serum pregnancy test at Screening and negative urine pregnancy test at Baseline (Day  1). 
Tapi[INVESTIGATOR_402197] -505-3001  
Dermavant Sciences GmbH  Clinical Study Protocol – Version 2.0  
Confidential  Page | 14 5. Capable of giving written informed consent, as applicable, which includes compliance with the 
requirements and restrictions listed in the  informed consent form  (ICF) ; written informed consent must be 
obtained prior to any study related procedures.  
Exclusion Criteria: 
A subject who meets any of the following criteria will be excluded and considered ineligible for participation in 
the study:  
1. Psoriasis other than plaque variant . 
2. Any sign of infection of any of the psoriatic lesions . 
3. Concurrent conditions or history of other diseases:  
a. Immunocompromised (eg, lymphoma, acquired immunodeficiency syndrome)  or medical history of 
positive human immunodeficiency virus (HIV) antibody at Screening.  
b. Chronic or acute systemic infection requiring treatment with systemic antibiotics, antivirals, 
antiparasitics, antiprotozoals, or antifungals within 4 weeks prior to the Baseline visit.  
c. Acute active bacterial, fungal, or viral (herpes simplex, herpes zoster, chicken pox) skin infection 
within 1 week prior to the Baseline visit. 
d. Significant dermatologic or inflammatory condition other than plaque psoriasis that, in the Investigator’s opi[INVESTIGATOR_1649], would make it difficult to interpret data or assessments during the study.  
4. Screening alanine aminotransferase (ALT) or aspartate aminotransferase (AST) ≥ 1.5x the upper limit of 
normal  (ULN).  
5. Screening total bilirubin > 1.[ADDRESS_506833]; total bilirubin >  ULN and ≤ 1.[ADDRESS_506834] bilirubin < 35%.  
6. Corrected QT (QTcF) interval > 475 m sec. 
7. Current or chronic history of liver disease, known hepatic  or biliary abnormalities (with the exception of 
Gilbert’s syndrome or asymptomatic gallstones), presence of hepatitis B surface antigen (HBsAg), or 
positive hepatitis C antibody test result, or a positive anti -hepatitis B core antigen (anti- HBc) result . 
Subject s with a history of HCV infection who were medically cured and have an undetectable viral load 
are eligible to enroll.   Subjects with  a history of stable non- alcoholic fatty liver disease without evidence 
of active inflammation (elevated ALT/AST ≥  1.5x ULN) or cirrhosis  are eligible to enroll.   
8. Ultraviolet (UV) light therapy or prolonged exposure to natural or artificial sources of UV r adiation 
(eg, phototherapy, tanning beds/booths, or therapeutic sunbathing) within 4 weeks prior to the Baseline 
visit and/or plans to have such exposures during the study (double -blind and open- label phases) which 
could potentially impact the subject’s ps oriasis (as determined by [CONTACT_737]) . 
9. Use of any prohibited medication within the indicated period before the Baseline visit.  
NOTE :  Prohibited concomitant medications, therapy, etc., during the defined period are as listed in the 
bullets below .  If a subject requires any of these medications throughout the study period, he/she may be 
excluded from  or discontinued from the study.  
• Minimum of 5 half-lives for biologic agents :  eg, 1 2 months for rituximab; 8 months for 
ustekinumab; 5 months for secukinumab; 1 2 weeks for golimumab; 1 0 weeks for ixekizumab; 
8 weeks for infliximab, adalimumab, or alefacept; and 4 weeks for etanercept  
• 4 weeks for systemic treatments :  cyclosporin, interferon, methotrexate, apremilast, tofacitinib, 
mycophenolate, thioguanine,  hydroxyurea, sirolimus, azathioprine, other systemic 
immunosuppressive or immunomodulating agents, fumaric acid derivatives, vitamin D 3 and analogs  
(> 5000 IU/day) , retinoids (eg,  acitretin, isotretinoin), psolarens, corticosteroids, or 
adrenocorticotropic hormone analogs  
• 2 weeks for immunizations with a live viral component; drugs known to possibly worsen psoriasis, 
such as beta- blockers (eg, propranolol), lithium, iodides, angiotensin- converting enzyme inhibitors, 
and indomethacin, unless on a stable dose for > 12 w eeks 
Tapi[INVESTIGATOR_402197] -505-3001  
Dermavant Sciences GmbH  Clinical Study Protocol – Version 2.0  
Confidential  Page | 15 • With the exception of non-medicated emollients, 2 weeks for topi[INVESTIGATOR_402202], antihistamines, immunomodulators, anthralin (dithranol), Vitamin D derivatives (eg, 
calcipotriene, calcipotriol), retinoids ( Note :  4 weeks for tazarotene), or coal tar  
10. A history of or ongoing serious illness or medical, physical, or psychiatric condition(s) that, in the 
Investigator’s opi[INVESTIGATOR_1649], may interfere with the subject’s participation in the study and ability to understand 
and give informed consent.  
11. Pregnant females as determined by [CONTACT_222190] (screening) or urine (baseline) human chorionic gonadotropin test at sc reening or prior to dosing.  
12. Lactating females.  
13. History of sensitivity to the study drugs, or components thereof or a history of drug or other allergy that, in the opi[INVESTIGATOR_24245], contraindicates the subject’s participation in the study.  
14. The subject has received an investigational product within the following time period prior to the first 
dosing day in the current study:  [ADDRESS_506835] of the 
study drug (whichever is lon ger). 
15. Current or a history of cancer within 5 years except for aqequately treated skin basal cell carcinoma, 
squamous cell carcinoma or carcinoma in situ of the cervix (surgical excision or electrodessication and 
curettage) . 
16. Subjects with active  systemic  infection that required oral, intramuscular, or intravenous administration of 
antibiotics, antifungal or antiviral agents within 4 weeks  of Baseline/ Day 1. 
17. Concurrent skin lesions in the treatment area that, in the opi[INVESTIGATOR_689], would eithe r interfere 
with study evaluations or affect the safety of the subject.  
18. Subjects with advanced disease or abnormal laboratory test values that could affect the safety of the 
subject or the implementation of this study.  
19. Previous known participation in a clinical study with tapi[INVESTIGATOR_191752] . 
20. Evidence of significant hepatic, renal, respi[INVESTIGATOR_696], endocrine, hematologic, neurologic, psychiatric, or cardiovascular ( CV) system abnormalities or laboratory abnormality that will affect the health of the 
subject or interfere with interpretation of the results.  
Investigational Product, Dosage and Mode of Administration:  
Tapi[INVESTIGATOR_191753], 1% is a white to off -white cream containing 1% (10  mg/gram) tapi[INVESTIGATOR_191752], supplied in 30- gram 
tubes, and is to be self-administered once daily via topi[INVESTIGATOR_55594] a thin layer to affected areas .   
Reference Therapy, Dosage and Mode of Administration : 
Vehicle  cream is a white to off -white cream , supplied in 30- gram tubes, and is  to be self -administered once dai ly 
via topi[INVESTIGATOR_55594] a thin layer to affected areas .   
Duration of T reatment :  Study duration for subjects who complete this Phase  [ADDRESS_506836] not to enroll in that study  is approximately 20 w eeks in total (including approximately 34 days 
screening, 12  weeks of treatment , and a 4- week follow -up period).  
• Subjects randomized to tapi [INVESTIGATOR_191753], 1% will receive tapi[INVESTIGATOR_222158] 12 weeks.  
• Subjects randomized to vehicle cream will receive treatment with vehicle cream for 12  weeks.  
Criteria for Evaluation : 
Efficacy Assessments:  Investigator assessment of PGA, %BSA affected, and Psoriasis Area Severity Index  
(PASI ). 
Functional Outcomes and Quality of Life Assessments :  Dermatology Life Quality  Index (DLQI ), Psoriasis 
Symptom Diary ( PSD), Short Form -36 (SF-36), and Peak P ruritus -Numeric Rating Scale (NRS).  
Safety Assessments:  AEs, vital signs, physical examinations, clinical laboratory tests, and Local Tolerability 
Scale ( LTS). 
Pharmacokinetic Assessments :  Plasma concentration of tapi[INVESTIGATOR_191752].  
Study Endpoints:  
Tapi[INVESTIGATOR_402197] -505-3001  
Dermavant Sciences GmbH  Clinical Study Protocol – Version 2.0  
Confidential  Page | 16 Primary : 
• Proportion of subjects who achieve a PGA score of clear (0) or almost clear (1) with a minimum 2 -grade 
improvement from Baseline at Week  12 
Secondary:  
• Proportion of subjects with ≥ 75% improvement in PASI from Baseline at Week  12 
• Proportion of subjects with a PGA score of 0 or 1 at Week  12 
• Mean change in percent of total body surface area (%BSA) affected from Baseline to Week  12 
• Proportion of subjects with ≥ 90% improvement in PASI score from Baseline to Week 12  
Exploratory Endpoints  
• Time to achieve a PGA score of 0 or 1 with a minimum 2 grade improvement from Baseline  
• Change in Peak Pruritus -Numeric  Rating Scale ( Peak Pruritus -NRS) from Baseline at Weeks 2, 4, 8, and 
12 
• Proportion of subjects with a PGA score of 0 or 1 at Weeks 2, 4, 8, and 12  
• Proportion of subjects who achieve a PGA score of 0 or 1 with a minimum 2 -grade improvement from 
Baseline at Weeks 2, 4, and 8 
• Mean absolute and percent change in PASI score from Baseline to Weeks 2, 4, 8, and 12  
• Proportion of subjects with ≥ 50% improvement in PASI score from Baseline to Weeks 2, 4, 8, and 12  
• Proportion of subjects with ≥ 75% improvement in PASI score from Baseline to weeks 2, 4, and 8  
• Proportion of subjects with ≥ 90% improvement in PASI score from Baseline to weeks 2, 4, and 8 
• Mean change in %BSA affected from Baseline to Weeks 2, 4, and 8  
• Change over time in psoriasis impact on daily activities, as measured by [CONTACT_402238]  
• Change over time in psoriasis symptoms, as measured by [CONTACT_402239]  
• Change over time in physical component score and mental component score, as measured by [CONTACT_402240]-36 q uestionnaire  
Safety:  
• Incidence, frequency, and duration of treatment emergent adverse events (TEAEs) and serious adverse events (SAEs)  
• Clinically significant change from Baseline in laboratory values  
• Clinically significant change from Baseline in vital signs  
• Mean LTS scores by [CONTACT_402241]: 
• Plasma concentration of tapi[INVESTIGATOR_222164] 4 and 12  
Statistical Methods:  
Determination  of Sample Size:  It is assumed that the proportion of subjects who achieve PGA score of clear (0) or 
almost clear (1) with a minimum 2 -grade improvement from Baseline at Week  12 w ill be 40% for subjects 
receiving tapi[INVESTIGATOR_191753] , 1% compared with 15% for subjects receiving vehicle control cream .  With 
500 s ubjects randomized in a 2: 1 ratio (approximately 333 s ubjects receiving tapi[INVESTIGATOR_191753], 1% and 
approximately [ADDRESS_506837] s receiving vehicle cream), there will be > 99% power for a statistical significance 
(2-sided p< 0.05).  If the tapi[INVESTIGATOR_402203] 35%, and the vehicle response rate is 20%, the power will be 
> 94%.  The power is calculated from a Fisher Exact sample size calculation which is conservative.   It is assumed 
that up to 25% of the subjects will be los t to follow -up by 12 w eeks.  These subjects will be included in the 
primary analysis using the multiple imputation method.  
Efficacy Analyses :  All efficacy analyses will be based on the Intent -to-Treat (ITT) population and will be 
repeated for the Per Prot ocol (PP) population only for the primary and secondary efficacy endpoints as supportive 
analysis .  The primary efficacy endpoint will be analyzed using a Cochran– Mantel –Haenszel (CMH) test stratified 
by [CONTACT_402242] (PGA scores of 2, 3, or 4) .  The same method  used for the primary analyses will be used 
to analyze all dichotomized secondary  endpoints .  The secondary endpoints will be tested sequentially in order, 
and testing will stop if non -significance (2 -sided p ≥ 0.05) is observed .  Other efficacy endpoints will be analyzed 
Tapi[INVESTIGATOR_402197] -505-3001  
Dermavant Sciences GmbH  Clinical Study Protocol – Version 2.0  
Confidential  Page | [ADDRESS_506838] for proportions, and analysis of covariance ( ANCOVA ) model for continuous variables .  CMH 
tests will be stratified by [CONTACT_402243], and ANCOVA models will include PGA score as a covariate.   
Open -label data will be summarized using summary statistics without testing.  
Safety Analyses :  The Safety Population will be used in the analysis of safety data .  Data will be listed by [CONTACT_402244] .  No formal statistical comparis ons will be made for safety data .  The 
number and proportion of subjects with TEAEs will be summarized by [CONTACT_3148], system organ class, and 
preferred term for all TEAEs, all TEAEs considered by [CONTACT_66325], all SAEs, and 
all TEAEs leading to study drug discontinuation. All TEAE summaries will include information for AEs that 
occurred after administration of the first dose of study drug until completion of the final study visit .  Data listings 
will be provided for subjects who discontinued the study due to an AE and for subjects with an SAE .  Selected 
laboratory data will be analyzed using descriptive summary statistics and will be presented by [CONTACT_402245], including the number of non -missing observations, mean and standard deviation, median, upper 
and lower quartiles, minimum and maximum for values and changes from Baseline .  Categorical safety data will 
be analyzed using frequency tables and, if applicable, shift tables.  
Functional Outcomes and Quality of Life Analysis:   Change from Baseline in the subject reported DLQI , PSD, 
SF-36, and Peak P ruritus -NRS  scores  will be analyzed  using an ANCOVA model with treatment as a main effect, 
and baseline as a covariate. 
Pharmacokinetic Analyses :  Plasma co ncentrati on data will be listed and  summarized by [CONTACT_15449] . 
 
Tapi[INVESTIGATOR_402197] -505-3001  
Dermavant Sciences GmbH            Clinical Study Protocol  
Confidential  Page 18 SCHEDULE OF ASSESSMENTS  
Table 1: Schedule of Assessments 
Procedures and Assessment  Screening  Baseline  Double -Blind Vehicle -Controlled Treatment Phase  FUa ETb 
V 1 V 2 V 3 V 4 P/Cc V 5 P/CcV 6 V 7 NA 
Day -34 
to 
Day -1 Day 1 Week  
2 
D 15 
(±2 d) Week  
4 
D 29 
(±2 d) Week  
6 
D 43 
(±2 d) Week  
8 
D 57 
(±2 d) Week  
10 
D 71 
(±2 d) Week  
12 
D 85 
(±2 d) Week  
16 
D 113 
(±4 d) NA 
Informed consent  X 
Demographics X 
Medical historyd X Xe 
Assess/confirm eligibility  X X 
Serum/urine pregnancy test ( WOCBP)f X Xg X X X X X 
Brief physical examination  Xh X X X X X X 
Vital signsi X X X X X X X X 
ECG X 
Blood sample for clinical laboratory testsj X X X X X 
Urinalysis  X X X 
HADS  X 
Subject r andomization  X 
Photograph representative area of  disease areak X X X X 
PK blood sample collectionl X X 
Adverse events X X X X X X X X X X 
Concomitant medication  X X X X X X X X X X 
Investigator Assessed:   
PGA scorem X X X X X X X X 
%BSA affectedn X Xo X X X X X X 
PASI  X X X X X X X 
LTSp X X X X X X 
Tapi[INVESTIGATOR_402204] -505-3001  
Dermavant Sciences GmbH                                                                                                                                                                                 Clinical Study Protocol  
Confidential  Page 19 Procedures and Assessment  Screening  Baseline  Double -Blind Vehicle -Controlled Treatment Phase  FUa ETb 
V 1 V 2 V 3 V 4 P/Cc V 5 P/Cc V 6 V 7 NA 
Day -34 
to  
Day -1 Day 1 Week  
2 
D 15 
(±2 d) Week  
4 
D 29 
(±2 d) Week  
6 
D 43 
(±2 d) Week  
8 
D 57 
(±2 d) Week  
10 
D 71 
(±2 d) Week  
12 
D 85 
(±2 d) Week  
16 
D 113 
(±4 d) NA 
Completed by [CONTACT_27720]:              
DLQI   X  X    X X X 
SF-36  X  X    X X X 
PSD  X X X  X  X X X 
LTS   X X  X  X X X 
Peak Pruritus NRSq  X X X X X X X X X 
Dispense/collect diaryr  D C/D C/D  C/D  C  C 
Review subject diaries for treatment compliance   X X  X  X  X 
Dispense (D)/Collect (C) study drug   D C/D C/D  C/D  C  C 
Review instructions for study drug applications  X X X X X X    
Study drug application under supervisiont  X X X  X     
Enrollment (optional) in long-term study         X   
AE = adverse event (s); BMI = body mass index; BSA = body surface area; %BSA = percent of total BSA; D/d  = day(s); DLQI  = Dermatology Life Quality Index; ECG  = electrocardiogram; eCRF = 
electronic Case Report Form; ET  = early termination; FU  = follow -up; HADS  = Hospi[INVESTIGATOR_5620]; LTS  = Local Tolerability Scale; NA  = not applicable; NRS  = Numeric Rating 
Scale; PASI  = Psoriasis Area and Severity Index; P/C  = phone contact; PGA = Physician Global Assessment; PK  = Pharrmacokinetics; PSD = Psoriasis Symptom Diary; SF -36 = 36−Item Short Form 
Survey; V  = Visit; WOCBP = women of child- bearing potential.  
 
a The Follow -Up Visit will be performed for any subject who:  (a) prematurely withdraws from the study, (b) fails to qualify for participation in the open -label long -term study, or (c) qualifies to 
participate in the open -label long -term study but elects not to enroll in that study . 
b Subjects who withdraw from the study before 12 weeks (Visit 6) will complete an Early Termination Visit.  
c Phone calls are scheduled between visits to assess AEs and concomitant medications, to review study drug application procedures, and to confirm subject’s continued participation in the study.  
Subjects should be reminded to complete the diary and bring with them to the next clinic visit . 
d Medical history will include year of plaque psoriasis diagnosis, CV medical history and risk fact ors (including height, weight, smoking history, medical conditions, and family history of premature CV 
disease) and family history of liver disease . 
e Record any changes to medical history.  
f Serum pregnancy  test to be performed at the Screening visit only and urine pregnancy test to be performed at subsequent clinic visits . 
g Urine pregnancy test  to be performed before randomization . 
h Physical examination  will include height, weight, and BMI at the Screening visit; a brief physical examination will be performed at other visits (Section  6.3.2 ). 
Tapi[INVESTIGATOR_402204] -505-3001  
Dermavant Sciences GmbH                                                                                                                                                                                 Clinical Study Protocol  
Confidential  Page 20 i Vital signs will include  blood pressure, pulse, and body temperature . 
j Including serum chemistry  and liver chemistry tests, and hematology . 
k Photography will be performed  in a subgroup of subjects at selected (8 to 10) study centers; this is not required of subjects for participation in the study.  Informed consent/assent and photographic 
release will be required.  
l Blood sample collection for PK will be performed at a subset of sites in a subset of subjects.  Sample to be collected prior to study drug application in cl inic. 
m The PGA assessment  should be pe rformed before the %BSA and PASI assessments .  
n The subject’s scalp, palms, fingernails  toenails, and soles should be excluded from the %BSA calculations . 
o %BSA affected calculation should be completed before the PASI assessment.  Note that lesions on scalp, palms, fingernails, toenail s, and soles will not be included in the calculation of %BSA 
affected as these areas will be excluded from the efficacy analyses . 
p The LTS assessment  also consists of a subject -assessed component ( Section  6.3.5 ). 
q Subjects should perform  the Peak Pruritus NRS assessment daily ( Section  [IP_ADDRESS] ) and record the results in their diary . On study visit days, subjects will not complete the diary at home; application 
time and N RS will be recorded in the clinic.  
r Subjects will be instructed on when and how to complete diaries . 
s Subjects will be instructed to apply  study drug once daily at the approximate same time each day, based on subject preference ( Section  5.1.5 ). 
t At clinic visits , study drug will be  applied after safety and efficacy assessments have been conducted (see Section  5.1.5  for additional details on timing of application of study drug d uring clinic 
visits).  
 
 
 
Tapi[INVESTIGATOR_402197] -505-3001  
Dermavant Sciences GmbH.  Clinical Study Protocol – Version 2.0  
Confidential  Page | 21 1. INTRODUCTION 
1.1. Background Information and Study Rationale  
1.1.1. Background Information  
Psoria sis is a common, chronic relapsing inflammatory skin disease [ Paris i, 2012] with recurrent 
epi[INVESTIGATOR_191760] (plaques).  Approximately 2 % to 3% of 
the global population is affected by [CONTACT_22803]; those affected are predominantly adults, who are 
most often diagnosed between the ages of 18 to 35 years .  Psoriasis disrupts daily activities such 
as work and/or school attendance, interpersonal relationships, recreational activities, and 
intimacy , thereby [CONTACT_191827]’ quality of life.  Furthermore, psoriasis 
sufferers can also have co -morbidities such as arthritis, depression, inflammatory bowel disease, 
and cardiovascular (CV) diseases . 
Up to 80% of patients have mild to moderate plaque-type psoriasis, which is generally managed 
with topi[INVESTIGATOR_12969] .  The most commonly used treatments for psoriasis include t opi[INVESTIGATOR_402205] D analogs, alone or in combination.  Vitamin D analogs are 
moderately efficacious  as monotherapy, whereas  application of topi[INVESTIGATOR_11930], 
particularly the very potent ones, is restricted in terms of body areas that can be treated and the 
duration of use due to the well-known application site and systemic adverse drug reactions 
[Mason, 2013].  Although numerous topi[INVESTIGATOR_191762], there remains a need 
for a topi[INVESTIGATOR_279969] a high level of efficacy with an acceptable safety profile 
and permits application to a large body surface area (BSA) without restrictions on duration of treatment.  
Tapi[INVESTIGATOR_191752] ( DMVT -505), formerly known as [COMPANY_004]2894512, is a fully synthetic hydroxylated 
stilbene that is being developed by [CONTACT_402246] (Dermavant) as a novel 
anti-inflammatory agent for the topi[INVESTIGATOR_22787] (AD) and plaque psoriasis .  
The compound (number WBI 1001) was initially developed by [CONTACT_191829].  
(Welichem; Burnaby, British Columbia, Canada) and then was acquired by [CONTACT_35316] 
([COMPANY_004]) on [ADDRESS_506839] of the world except China.  Beijing 
Wenfeng Tianji Pharmaceuticals (BWTP) is developi[INVESTIGATOR_007] a compound in China identified as 
Benvitimod (active ingredient corresponds to tapi[INVESTIGATOR_191752]) with a unique topi[INVESTIGATOR_59420].  Dermavant acquired the drug from [COMPANY_004] on [ADDRESS_506840] 2018 for continued development. 
Tapi[INVESTIGATOR_191753] , 1% is a white to off-white, oil- in-water emulsion intended for topi[INVESTIGATOR_191764], which has a novel mechanism of action.  The drug 
likely mediates its effects via the aryl hydrocarbon receptor  (AhR) agonis t and nuclear factor 
erythroid 2- related factor  2 (Nrf2) because the pattern of pro -inflammatory mediators inhibited 
by [CONTACT_66597][INVESTIGATOR_191765], calcineurin inhibitors, vitamin D analogs, and other immunosuppressive agents commonly used to treat AD and psoriasis.  Rather, the 
profile of biological responses elicited by [CONTACT_66597][INVESTIGATOR_191766], a common nonprescription treatment for psoriasis.  Together, 
existing data identify tapi[INVESTIGATOR_191767] a non-steroid, therapeutic AhR-modulating agent (TAMA), 
which is a unique mechanism of action compared with existing therapi[INVESTIGATOR_014]. 
Tapi[INVESTIGATOR_402206] 8% and in 
clinic al studies at concentrations up to 2%.  Three Phase 1 clinical pharmacology studies in 
healthy volunteers and 7 Phase 1/[ADDRESS_506841] been 
Tapi[INVESTIGATOR_402197] -505-3001  
Dermavant Sciences GmbH.  Clinical Study Protocol – Version 2.0  
Confidential  Page | 22 completed .  Refer to the current version of the tapi[INVESTIGATOR_222161]’s Brochure for detailed 
information .  Tapi[INVESTIGATOR_402207] a clear therapeutic 
effect, as compared with vehicle, in both psoriasis and AD. 
Four randomized, double-blind, vehicle- controlled, clinical studies to evaluate the safet y and 
efficacy of topi[INVESTIGATOR_402208]; one 28 -day and one 12-week study was completed for each indication. 
These studies enrolled a total of 282 adult subjects, with 235 s ubjects exp osed to tapi[INVESTIGATOR_222150], 0.5%, 1%, or 2% (Formulation C) once or twice daily for a period of [ADDRESS_506842] frequently 
reported (1% to  6% of 235 subjects) dermatological adverse events (AEs), regardless of 
causality, were application site discoloration/hyperpi[INVESTIGATOR_371], application site dermatitis, papular ras h, pruritus, dermatitis contact , folliculitis, erythema, and skin burning sensation.  
Nasopharyngitis and headache were the most frequently reported (> 10% of subjects) nondermatological AEs overall.  Overall, results of the clinical studies indicated tapi[INVESTIGATOR_402209], with a favorable safety profile. 
The first clinical study with Formulation F (Study 201851) was a Phase 1 study to evaluate the 
systemic exposure and pharmacokinetic ( PK) parameters of tapi[INVESTIGATOR_191753] , 1% and 2%.  This 
study was conducted in 11 s ubjects with AD; 5 subjects were treated with the 2% dose and 
6 subjects were treated with the 1% dose.  Headache was the most frequently reported ( 100% 
and 60% of subjects at the 1% and 2% doses, respectively) nondermatological AE . 
Two Phase 2b, 12 week, randomized, double-blind, vehicle-controlled, 6-arm, parallel group, 
dose-finding studies with topi[INVESTIGATOR_191773]; 1 study each in subjects with AD or psoriasis.  These 2 studies evaluated the safety and efficacy of 
tapi[INVESTIGATOR_191753] (Formulation F) at 2 concentrations (0.5% or 1%) and 2 a pplication frequencies 
(once daily or twice daily ) in [ADDRESS_506843] compared with vehicle, with the 1% concentration treatment groups demonstrating a higher 
proportion of subjects with treatment success compared with the 0.5% concentration groups 
(applied once daily and twice daily  in the AD study).  In both indications, the tapi[INVESTIGATOR_191752] 1% 
dosing groups showed a faster onset of action than the 0.5% dosing groups, and once daily 
application had similar efficacy to twice daily application .  In both Phase 2b studies, tapi[INVESTIGATOR_402210].  T reatment -emergent adverse events (TEAEs) were reported 
with a higher frequency in the tapi[INVESTIGATOR_402211].  The most frequent TEAEs ( ≥  5% in any arm or in total) were nasopharyngitis, folliculitis, dermatitis contact,  atopic 
dermatitis, upper respi[INVESTIGATOR_1092], headache, vomiting, acne, application site dermatitis, 
miliaria, dermatitis allergic , and impetigo.  The majority of TEAEs were m ild or moderate in 
severit y.  In each study, the tapi[INVESTIGATOR_191752] 1% once daily treatment group had a lower frequency of 
TEAEs than the tapi[INVESTIGATOR_191752] 1% twice daily treatment group. 
1.1.2. Study Rationale 
This pi[INVESTIGATOR_9205] 3 study is being conducted as part of a clinical development program to 
evaluate the efficacy and safety of tapi[INVESTIGATOR_191753] , 1% for the topi[INVESTIGATOR_402212] .  The results of this study are intended to support product 
registration in the [LOCATION_002].  
Tapi[INVESTIGATOR_402197] -505-3001  
Dermavant Sciences GmbH.  Clinical Study Protocol – Version 2.0  
Confidential  Page | 23 1.2. Rationale  for Study Design, Dose, and Control Groups  
This study is a 1 2 week double-blind, vehicle-controlled t reatment study in which subjects will 
be randomized to receive tapi[INVESTIGATOR_191753] , 1% or vehicle cream once daily for [ADDRESS_506844] historically shown a notable vehicle (as well 
as placebo) response rate, which could be attributable to the effects of skin moisturization or to the increased emphasis on proper skin care while participating in a clinical study.  A vehicle 
control group is included to provide a control for comparison and to ensure study sensitivity for characterization of the safety and efficacy profile of tapi[INVESTIGATOR_191753] , 1%. 
Subjects who complete this Phase [ADDRESS_506845] the option to enrol l in a separate open -label 
long-term safety and efficacy study for an additional 40 w eeks of treatment .  Subjects who do 
not enroll in the open- label long -term study will complete a follow -up visit approximately 
4 weeks after end of treatment in this study (at  Week  16). 
Tapi[INVESTIGATOR_402213]  0.5% to 8.0% and 
at once daily and twice daily dosing frequencies.  The 1% concentration applied once daily was  
chosen as the dose and dosing frequency to take forward in the clinical development program based on the data from [COMPANY_004] Phase 2b clinical Study 203120.  In that study, applications of 
tapi[INVESTIGATOR_402214] 0.5% and 1% applied once or twice daily  were evaluated .  Overall, 
both concentrations demonstrated an acceptable safety profile when applied once or twice daily .  
A faster onset  of action was observed with 1% dosing groups compared with the 0.5% dosing 
groups in both studies ; fast onset of action is an important consideration for topi[INVESTIGATOR_5910] .  
A once daily  application regimen may reduce systemic exposure as the skin heals , thereby 
[CONTACT_1541] a better safety profile for a drug intended for long- term use to treat a chronic 
condition.  In addition, once daily application may improve treatment adherence compared with  
more frequent dosing administrations .  Based on the efficacy and safety data fro m Study 203120, 
1% once daily was chosen as the tapi[INVESTIGATOR_402215]. 
1.3. Potential Risks and Benefits 
To assess any potential impact on subject eligibility with regard  to safety, the Investigator must 
refer to the current version of the tapi[INVESTIGATOR_191769] ’s Brochure for detailed information 
regarding warnings, precautions, contraindications, AEs , and other significant data pertaining to 
the study drug being used in this study. 
1.3.1. Risk Assessment  
[IP_ADDRESS]. Dermatological Adverse Event s, Including Skin Irritation or Allergic Reaction  
Tapi[INVESTIGATOR_191782] .  Allergic or irritant reactions in the 
exposed areas may present as erythema, edema, papules, or vesicles .  In the event of pronounced 
Tapi[INVESTIGATOR_402197] -505-3001  
Dermavant Sciences GmbH.  Clinical Study Protocol – Version 2.0  
Confidential  Page | 24 skin reaction, spreading of the eczematous reaction beyond the original application site(s) and/or 
more generalized (remote) skin reactions may be observed. 
In the dose-ranging Study [ADDRESS_506846] 
frequently reported dermatologic AEs were folliculitis and AD.  Nonclinical dermal toxicity 
studies of up to 8% tapi[INVESTIGATOR_191783] 13 weeks indicated local effects are primarily 
mild-to-moderate skin irritation that is reversible; tapi[INVESTIGATOR_402216] .  In initial clinical studies using a d ifferent formulation of tapi[INVESTIGATOR_191752] 
(Formulation  C), AEs of skin hyperpi[INVESTIGATOR_371], application site dermatitis, papular rash, 
pruritus, contact [CONTACT_8748], folliculitis, erythema, and skin burning sensation were reported. 
To mitigate these potential risks , subjects  with a known or suspected intolerance to tapi[INVESTIGATOR_402217].  Subject s’ skin will be evaluated routinely for 
signs of irritation or allergic reaction, and if needed, study treatment may  be interrupted and an 
appropriate treatment provided.   
[IP_ADDRESS]. Systemic Adverse Event s 
Nasopharyngitis and headache were the most frequently-reported nondermatological AEs in 
dose-ranging Study [ADDRESS_506847] 
infection , and headache.  In the initial clinical studies (in AD and psoriasis) using a different 
tapi[INVESTIGATOR_402218] (Formulation C), nasopharyngitis, and headache were the most frequently 
reported nondermatological AEs.  In the open -label PK Study 201851 w ith BID dosing of 
Formulation F of tapi[INVESTIGATOR_191753] (n=11), 1% and 2%, headache was the most frequently reported during the study (reported for 100% and 60% of subjects at the 1% and 2% doses, 
respectively).  
In a nonclinical study in minipi[INVESTIGATOR_402219] ( IV) administration, reversible decreases in 
arterial blood pressure and PR interval were observed; however, in this study and repeat dermal 
toxicity studies , there were no effects on QT interval or heart rate.  Repeat -dose dermal toxicity 
studies also showed findings related to the liver (increased weights and hepatocellular 
hypertrophy/regeneration) and thymus (thymic cortex depletion in adult rabbits and rats; changes in thymus weight, microscopic decreased cellularity, and changes in thymic T cell maturation in 
juvenile rats)  with associated secondary hematological findings.  Thymic findings were also 
noted in repeat adult and juvenile rat studies; however, there were no clinically relevant AEs/ serious adverse events ( SAEs ) reported . 
To mitigate potential systemic risks, subject s will be monitored for AE s and  any abnormal vital 
signs, physical examination, and laboratory test results. 
[IP_ADDRESS]. Reproductive and Developmental T oxicity  
Results of embryo-fetal development studies in rats and rabbits indicated an increased risk for 
embryo- fetal developmental effects , as evi denced by [CONTACT_191830]-implantation loss and 
incidence of fetal skeletal variations .  Results of a juvenile rat study indicated adverse 
microscopic changes in the form of renal pelvic dilatation in both sexes, along with reversible increases in total urinary glucose and protein excretion in males at ≥  10/15 mg /kg/day tapi[INVESTIGATOR_191752] 
(administered subcutaneously). 
Tapi[INVESTIGATOR_402197] -505-3001  
Dermavant Sciences GmbH.  Clinical Study Protocol – Version 2.0  
Confidential  Page | 25 An investigative study in rats suggested an increased risk for hydronephrosis during a narrow 
window of postnatal sensitivity prior to postnatal day (PND) 32 (specifically PND 1 5 to 21).  Rat 
renal tubule anatomic maturation and nephrogenesis occurs during this period [Cappon, 2010; 
Frazier, 2013; Zoetis, 2003] , however tubule morphogenesis/nephrogenesis occurs entirely 
prenatally in humans [Cappon, 2010; Zoetis, 2003] . 
To mitigate these potential risks , women of childbearing potential must utilize abstinence or a 
highly effective method of contraception consistently and correctly during the study and for 
4 weeks after the end of treatment ( Section  4.2).  Monthly pregnancy testing will be conducted.  
Pregnant women and subjects under [ADDRESS_506848] s may experience improvements in their psoriasis during the course of the study and may 
benefit from the additional safety assessments conducted as part of the study (eg, physical examination, laboratory tests).  Subject s in the study will also contribute to the process of 
developi[INVESTIGATOR_007] a novel anti- inflammatory agent for the topi[INVESTIGATOR_179802].  
1.3.3. Overall Benefit Risk  
Taking into account the measures taken to minimize risk to subject s in this study, the potential 
risks identified in associ ation with tapi[INVESTIGATOR_402220] s with psoriasis . 
Tapi[INVESTIGATOR_402197] -505-3001  
Dermavant Sciences GmbH.  Clinical Study Protocol – Version 2.0  
Confidential  Page | 26 2. OBJECTIVES AND ENDPO INTS  
The objectives and associated endpoints of the study are as follows: 
Objectives Associated Endpoint  
Primary  
• To evaluate the 
efficacy of tapi[INVESTIGATOR_222150],  1% compared 
with vehicle control in adults with plaque psoriasis  • Proportion of subjects who achieve a Physician Global Assessment (PGA) 
score of clear (0) or almost clear (1) with a minimum 2 -grade improvement 
from  Baseline at Week  12 
Secondary  
• To further characterize the efficacy of tapi[INVESTIGATOR_222150],  1% compared 
with vehicle control 
over time  Secondary:  
• Proportion of subjects with ≥ 75% improvement in Psoriasis Area and 
Severity Index (PASI) from Baseline at Week  12 
• Proportion of subjects with a PGA score of 0 or 1 at Week  12 
• Mean change in percent of total body surface area (%BSA) affected from Baseline to Week  12 
• Proportion of subjects with ≥90% improvement in PASI score from Baseline to Week 12  
Exploratory Endpoints : 
• Time to achieve a PGA score of  0 or 1 with a minimum 2 -grade 
improvement from Baseline  
• Proportion of subjects with a PGA score of 0 or 1 at Weeks 2, 4, 8, and 12 
• Proportion of subjects who achieve a PGA score of 0 or 1 with a minimum 
2-grade improvement from Baseline at Weeks 2, 4, and 8  
• Mean absolute and percent change in PASI score from Baseline to Weeks 2, 4, 8, and 12 
• Proportion of subjects with ≥ 50% improveme nt in PASI score from 
Baseline to Weeks 2, 4, 8, and 12 
• Proportion of subjects with ≥ 75% improvement in PASI score from Baseline to weeks 2, 4, and 8 
• Proportion of subjects with  ≥ 90% improvement in PASI score from 
Baseline to weeks 2, 4, and 8 
• Mean chang e in %BSA affected from Baseline to Weeks 2, 4, and 8 
• To describe the effect 
of tapi[INVESTIGATOR_191753] , 
1% on psoriasis 
symptom severity and 
the associated impact on daily activities and attitudes in adults 
with plaque psoriasis  • Change in Peak Pruritus- Numeric Rating Scale (Peak Pruritus- NRS)  from 
Baseline at Weeks 2, 4, 8, and 12 
• Change over time in psoriasis  impact on daily activities, as measured by 
[CONTACT_402247] (DLQI) total and individual dimension 
scores  
• Change over time in psoriasis symptoms, as measured by [CONTACT_402248] (PSD)  
• Change over time in physical component scor e and mental component 
score, as measured by [CONTACT_140491]-36 ( SF-36) questionnaire 
• To evaluate the safety 
and tolerability of tapi[INVESTIGATOR_191753], 1% Safety:  
• Incidence, freque ncy, and duration of treatment emergent adverse events 
(TEAEs) and serious adverse events (SAEs)  
Tapi[INVESTIGATOR_402197] -505-3001  
Dermavant Sciences GmbH.  Clinical Study Protocol – Version 2.0  
Confidential  Page | 27 Objectives  Associated Endpoint  
in adults with plaque 
psoriasis • Clinically significant change from Baseline in laboratory values  
• Clinically significant change from Baseline in vital signs  
• Mean Local Tolerability Scale (LTS) scores by [CONTACT_765]  
• To characterize the 
PK of tapi[INVESTIGATOR_402221] : 
• Plasma concentration of tapi[INVESTIGATOR_222164] 4 and 12 
Tapi[INVESTIGATOR_402197] -505-3001  
Dermavant Sciences GmbH.  Clinical Study Protocol – Version 2.0  
Confidential  Page | 28 3. STUDY DESIGN  
3.1. Overall Design  
This is a double-blind, randomized, vehicle-controlled, Phase 3, multicenter  study to evaluate the 
efficacy and safety of topi[INVESTIGATOR_222165] , 1% compared with vehicle- control cream in adults 
with plaque psoriasis.   
Following a 34-day screening period, eligible subjects will be randomized at a 2:1 ratio to 
receive once daily treatment with tapi[INVESTIGATOR_191753] , 1% or vehicle cream  for [ADDRESS_506849]’s  continued participation in this study. 
Study drug will be dispensed to subjects during the clinic visits and will be administered  at home 
between clinic visits as instructed by [CONTACT_8786].  S ubjects will be instructed to apply study 
drug once daily  to all affected areas , including newly appearing lesions and lesions /areas  that 
improve during the study.  Subjects will apply sufficient study drug to cover completely each 
lesion with a thin layer of study drug and will record the time of study drug application in a daily 
diary provided by [CONTACT_3452].  (Note that subjects are allowed, but not required, to treat 
fingernails, toenails, palms, soles, and scalp lesions with study drug; however, efficacy analyses 
will not include assessment of improvement of psoriasis in these areas .)  Subjects will be 
instructed to maintain the approximate dosing time chosen at the beginning of the study for their 
full study participation .  At the phone contacts at Weeks 6, and 10, subjects should be reminded 
to complete their daily  diary and bring it with them to the next clinic visit.  
Study drug application instructions will be reviewed at all post- randomization clinic visits and  
during any planned study phone calls.  On clinic visit days, subjects will be instructed/reminded 
on how to apply study drug (except during the final treatment/end -of-study visits ).  During the 
clinic visits, subjects will apply the daily dose of study drug while at the clinic under the 
supervision of site personnel, after efficacy and safety  assessments have been co mpleted .  The 
time of the d ose application and assessments will depend on the time of the clinic visit.  
Therefore, the timing of the clinic visit may lead to a change in  the subject’s chosen dosing time.  
At the end of the [ADDRESS_506850] not to enroll in that study, will complete a Follow -up Visit approximately 
4 weeks (Week  16 visit) after the end of treatment in this study.  Subjects who withdraw from the 
study before Week  [ADDRESS_506851] 
not to enroll in that study is approximately 20 weeks in total. Study duration for subjects who 
complete this Phase 3 study and are eligible and decide to participate in the open -label long- term 
study is approximately 16 weeks in total. 
Efficacy assessments will include Investigator assessment of PGA score, %BSA  affect ed, PASI, 
and subject-reported DLQI, SF -36, Peak P ruritus -NRS, and PSD .  Saf ety assessments will 
Tapi[INVESTIGATOR_402197] -505-3001  
Dermavant Sciences GmbH.  Clinical Study Protocol – Version 2.0  
Confidential  Page | 29 include AEs, clinical laboratory tests , physical exa mination, vital signs, and LTS .  
Pharmacokinetics will be assessed at a subset of sites in a subset of subjects  at Week  4 and 
Week  12. 
Refer to Section  6 for descriptions of study procedures and assessments and Section  7 and the 
Schedule of Assessments  (Table 1) for timing of procedures and assessments.  The study schema 
is presented in Figure 1.  
Figure 1:  Study Schema  
 
 
 
3.2. Treatment Groups and Duration  
This 12-week , Phase [ADDRESS_506852] s will be randomized in a 2:1 ratio to receive once daily treatment with either tapi[INVESTIGATOR_222150] , 1% or matching vehicle cream .   
At the conclusion of the [ADDRESS_506853] completed this study when he/she completes all required 
procedures/visits for the 12-week double-blind treatment phase . 
The end of study is defined as when the last active subject has completed t he Week  16 Follow-up 
Visit 4 w eeks after the end of treatment  (if subject does not enroll in the separate long -term 
study) OR the last active subject has completed the 12 w eeks of treatment  in this study ( if subject 
enrolls in the separate long -term study). 

Tapi[INVESTIGATOR_402197] -505-3001  
Dermavant Sciences GmbH.  Clinical Study Protocol – Version 2.0  
Confidential  Page | [ADDRESS_506854] m eet all of the following criteria to be eligible to participate in the study: 
1. Male and female subjects ages [ADDRESS_506855] 6 months prior to the study 
2. Body surface area inv olvement ≥ 3% and ≤ 20% ( the subject’s scalp, palms, fingernails, 
toenails, and soles should be excluded from the %BSA calculations). 
3. A PGA score of  2 (mild),  3 (moderate) or 4 (severe)  at screeni ng and baseline 
(pre-randomization).  Subject s with mild and severe psoriasis will be limited to 
approximately 10% each of the total randomized population; the majority of the enrolled 
subjects (approximately 80%) will have a PGA of 3, signifying moderate disease. 
4. Females of child -bearing potential and male subjects who are engaging in sexual activity 
that could lead to  pregnancy must use at least [ADDRESS_506856] exposure to study drug .  Acceptable 
contraception methods are: 
• Male partner with vasectomy, OR  
• Male condom AND partner use of one of the contraceptive options below: − Spermicide  
− Contraceptive subdermal implant that meets effectiveness criteria including 
a <  1% rate of failure per year, as stated in the product label 
− Intrauterine device or intrauterine system that meets effectiveness criteria including a < 1% rate of failure per year, as stated in the product label  
− Oral contraceptive, either  combined or progestogen alone 
− Injectable progestogen  
− Contraceptive vaginal ring 
− Percutaneous contraceptive patches 
NOTE :  Subjects using hormonal contraceptives must have been on a stable dose for at 
least [ADDRESS_506857] s understand how to properly use these methods of contraception. 
Non-child -bearing potential is defined as premenarchal or pre- menopausal  females with a 
documented bilateral tubal ligation, bilateral oophorectomy (removal of the ovaries) or 
Tapi[INVESTIGATOR_402197] -505-3001  
Dermavant Sciences GmbH.  Clinical Study Protocol – Version 2.0  
Confidential  Page | 31 hysterectomy , or hysteroscopic sterilization ; or postmenopausal females defined as a 
cessation of menses for at least 1 2 months without an alternative medical cause.  In 
questionable cases a blood sample with simultaneous follicle stimulating hormone (FSH) 
> 40 IU /mL is confirmatory .  Documented verbal history from the subject  is acceptable.  
Subjects  who are abstinent are eligible, but they must agree to use one of the birth control 
methods listed above if they start engaging in sexual activity that could lead to pregnancy during the study. 
Female subjects of childbearing potential must have a negative serum pregnancy test at 
Screening and  negative urine pregnancy test at  Baseline (Day  1). 
5. Capable of giving written informed consent, as applicable, which includes compliance 
with the requirements and restrictions listed in the informed consent form  (ICF) ; written 
informed consent must be obtained prior to any study related procedures. 
4.3. Exclusion Criteria  
A subject  who meets any of the following criteria will be excluded and considered ineligible for 
participat ion in the study: 
1. Psoriasis other than plaque variant 
2. Any sign of infection of any of the psoriatic lesions  
3. Concurrent conditions or history of other diseases: 
a. Immunocompromised (eg, lymphoma, acquired immunodeficiency syndrome) or medical 
history of positive human immunodeficiency virus (HIV) antibody at Screening  
b. Chronic or acute systemi c infection requiring treatment with systemic antibiotics, 
antivirals, antiparasitics, antiprotozoals, or antifungals within 4 weeks prior to the 
Baseline visit 
c. Acute active bacterial, fungal, or viral (herpes simplex, herpes zoster, chicken pox) skin infection within 1 week prior to the Baseline visit 
d. Significant dermatologic or inflammatory condition other than plaque psoriasis that, in 
the Investigator’s opi[INVESTIGATOR_1649], would make it difficult to interpret data or assessments during 
the study 
4. Screening alanine aminotransferase (ALT) or aspartate aminotransferase 
(AST) ≥ 1.5x the upper limit of normal (ULN) 
5. Screening total bilirubin > 1.[ADDRESS_506858]; total bilirubin >  ULN and ≤  1.[ADDRESS_506859] bilirubin < 35%. 
6. Corrected QT (QTcF ) interval > 475 m sec. 
7. Current or chronic history of liver disease, known hepatic or biliary abnormalities (with 
the exception of Gilbert’s syndrome or asymptomatic gallstones), presence of hepatitis B surface antigen (HBsAg), or positive hepatitis C antibody test result, or a positive anti -
hepatitis B core antigen (anti -HBc) result .  Subjects  with a history of HCV infection who 
were medically cured and have an undetectable  viral load  are eligible to enroll. Subjects 
with a history of stable non- alcoholic fatty liver disease without evidence of active 
inflammation (elevated ALT/AST ≥ 1.5x ULN) or cirrhosis are eligible to enroll. 
8. Ultraviolet (UV) light therapy or prolonged exposure to natural or artificial sources of 
UV radiation (eg, phototherapy, tanning beds/booths, or therapeutic sunbathing) within 
Tapi[INVESTIGATOR_402197] -505-3001  
Dermavant Sciences GmbH.  Clinical Study Protocol – Version 2.0  
Confidential  Page | 32 4 weeks prior to the Baseline visit and/or plans to have such exposures during the study 
which could potentially impact the subject’s psoriasis (as determined by [CONTACT_737]). 
9. Use of any prohibited medication within the indicated period before the Baseline visit. 
NOTE :  Prohibited concomitant medications, therapy, etc., during the defined period are 
as listed in the bullets below .  If a subject requires any of these medications throughout 
the study period, he/she may be excluded from or discontinued from the study. 
• Minimum of 5 half -lives for biologic agents:  eg, 12 months for ri tuximab; 8 months 
for ustekinumab; 5 months for secukinumab; 12 weeks for golimumab; 10 weeks  for 
ixekizumab; 8 w eeks for infliximab, ada limumab, or alefacept; and 4 weeks for 
etanercept.  
• 4 weeks for  systemic treatments:  cyclosporin, interferon, m ethotrexate, apremilast, 
tofacitinib, mycophenolate, thioguanine, hydroxyurea, sirolimus, azathioprine, other 
systemic immunosuppressive or immunomodulating agents, fumaric acid derivatives, 
vitamin  D3 and analogs (> 5000 IU / day), retinoids (eg, acitretin, isotretinoin), 
psolarens, corticosteroids, or adrenocorticotropic hormone analogs. 
• 2 weeks for immunizations with a live viral component; drugs known to possibly 
worsen psor iasis, such as beta-blockers (eg, propranolol), lithium, iodides, 
angiotensin-converting enzyme inhibitors, and indomethacin, unless on a stable dose 
for > 12 w eeks. 
• With the exception  of non-medicated emollients, 2 weeks for topi[INVESTIGATOR_402222], antihistamines, immunomodulators, anthralin (dithranol ), 
Vitamin D derivatives (eg , calcipotriene, calcipotriol), retinoids ( Note :  4 weeks for 
tazarotene), or coal tar.  
10. A history of or ongoing serious illness or medical, physical, or psychiatric condition(s) that, in the Investigator’s opi[INVESTIGATOR_1649], may interfere with the subject’s participation in the 
study and ability to understand and give informed consent. 
11. Pregnant females as determined by [CONTACT_222190] (screening) or urine (baseline) human chorionic gonadotropin test at screening or prior to dosing. 
12. Lactating females  
13. History of sensitivity to the study drugs, or components thereof or a history of drug or other allergy that, in the opi[INVESTIGATOR_24245], contraindicates the subject’s participation  in the study. 
14. The subject has received  an investigational product within the following time period prior 
to the first dosing day in the current study:  [ADDRESS_506860] of the study drug (whichever is longer). 
15. Current or a history of cancer within 5 years except for adequately treated  skin basal cell 
carcinoma, squamous cell carcinoma or carcinoma in situ of the cervix  (surgical excision 
or electrodessication and curettage) . 
16. Subjects with active systemic infecti on that required oral, intramuscular, or intravenous 
administration of antibiotics, antifungal or antiviral agents within 4 weeks  of 
Baseline/Day  1. 
17. Concurrent skin lesions in the treatment area that, in the opi[INVESTIGATOR_689], would either interfere with study evaluations or affect the safety of the subject. 
Tapi[INVESTIGATOR_402197] -505-3001  
Dermavant Sciences GmbH.  Clinical Study Protocol – Version 2.0  
Confidential  Page | [ADDRESS_506861] avoid UV light, phototherapy, and excessive sun exposure throughout the study.  When prolonged exposure cannot be avoided, use of sunscreen products (except on psoriasis 
plaques) and protective apparel are recommended.  
4.5. Screen ing/Baseline  Failures 
To determine subject eligibility at Screening and Baseline, a single repeat of tests or procedures may be allowed at the discretion of the Investigator ;   the Medical Monitor should be consulted if 
needed .   
Screen failures are defined as subject s who consent to participate in the clinical study but are not 
subsequently randomized .  A minimal set of screen failure information is required to ensure 
transparent reporting of screen failure subjects to meet the Consolidated Standards of Reporting Trials publishing requirements and to respond to queries from regulatory authorities.  Minimal information includes demography, screen failure details, eligibility criteria, and any SAEs.  
4.6. Withdrawal Criteria  
A subject  may voluntarily discontinue treatment and/or withdraw from participation in this study 
at any time  at his/her own request, or may be discontinued from study treatment at any  time at 
the discretion of the Investigator for safety, behavioral, compliance, or administrat ive reasons .  
Subjects withdrawn from the study will not be replaced.  
4.6.1. Reasons for Withdrawal from the Study  
Study drug will be  discontinued for any of the following reasons : 
• Subject has an AE that is considered to be related to study drug or procedures AND is severe enough to warrant treatment discontinuation, as determined by [CONTACT_737] (Section  8.1). 
• Subject requires concurrent prohibited medication during the study.  If, in the opi[INVESTIGATOR_402223], such medication will not interfere 
with the conduct or interpretation of the study or compromise the safety of the subject, then the subject may continue to receive study drug.  If the subject is 
discontinued from study drug, they may remain in the study for safety assessments as 
needed, at the discretion of the Investigator and M edical Monitor. 
• Pregnancy  
• Any Grade 3  or 4 AE considered causally related to study drug ( Section  8.2.2)  
Study drug may be discontinued for any of the following reasons: 
• Subject noncompliance 
Tapi[INVESTIGATOR_402197] -505-3001  
Dermavant Sciences GmbH.  Clinical Study Protocol – Version 2.0  
Confidential  Page | 34 • Investigator noncompliance 
• Discontinuation of the study at the request of the Sponsor, regulatory agency, or an 
Institutional Review Board (IRB)/Independent Ethics Committee (IEC). 
If a subject  meets a withdrawal criterion during treatment, an Early Termination visit will be 
required ( Section  7.5).  
4.6.2. Withdrawal Procedures  
The primary reason for the discontinuation of study drug and/or withdrawal from study must be 
recorded in the source document and  on the electronic case report form ( eCRF ).  If a subject  is 
prematurely discontinued from study drug(s), the Investigator must make every effort to perform an Early Termination Visit ( Section  7.5) and document the primary reason for withdrawal. 
Should a subject  fail to attend a required study visit, the site should attempt to contact [CONTACT_402249].  The site should also counsel the subject  on 
the importance of maintaining the assigned visit schedule and ascertain whether the subject wishes to and/or should continue in the study based on previous noncompliance.  In cases where 
the subject  does not return for the rescheduled visit or cannot be reached to reschedule the 
missed visit, the site should make every effort to regain contact [CONTACT_402250] a primary reason of “Lost to Follow-up”. 
4.7. Lost to Follow -Up 
A subject is considered lost to follow-up if he/she repeatedly fails to return to the study site for scheduled visits and is unable to be contact[CONTACT_9298].  The following actions must be taken if a subject fails to return to the clinic for a requ ired study visit: 
• The site must attempt to contact [CONTACT_402251]/or should continue in 
the study. 
• Before a subject is deemed lost to follow-up, the Investigator or designee must make every effort to regain contact [CONTACT_1155] (where possible, [ADDRESS_506862]’s l ast known mailing address or local 
equivalent methods).  These contact [CONTACT_402252]’s 
medical record.  
• Should the subject continue to be unreachable, he/she will be considered to have withdrawn from the study with a primary reason of lost to follow-up. 
Tapi[INVESTIGATOR_402197] -505-3001  
Dermavant Sciences GmbH.  Clinical Study Protocol – Version 2.0  
Confidential  Page | 35 5. STUDY TREATMENT  
5.1. Study Drug  
5.1.1. Description, Packaging, and Labeling  
The descriptions of the study drugs, tapi[INVESTIGATOR_191753], 1% and the vehicle cream , are presented in 
Table 2.  
Table 2: Tapi[INVESTIGATOR_402224] (DMVT -505) Vehicle C ream  
Physical description  White to off -white cream  White to off-white cream  
Unit dose  strength/ how supplied  1% (10 mg/gram) /30-gram tube  NA/30-gram tube  
Route of administration/ duration  Topi[INVESTIGATOR_2855]/12 weeks  Topi[INVESTIGATOR_2855]/12  week s 
Dosing instructions  Once daily t opi[INVESTIGATOR_402225] ( Section  5.1.5 ) Once daily t opi[INVESTIGATOR_402225] ( Section  5.1.5 ) 
Man ufacturer  GlaxoSmithKline  GlaxoSmithKlin e 
NA = not applicable.  
The excipi[INVESTIGATOR_402226], diethylene 
glycol monoethyl ether, polysorbate 80, medium chain triglycerides, emulsifying wax non-ionic, 
polyoxyl stearyl ether 2, polyoxyl stearyl ether 20, benzoic acid, butylated hydroxytoluene, 
purified water, sodium citrate, citric acid monohydrate, and edetate disodium. 
All labels fo r tapi[INVESTIGATOR_191755] , 1% and vehicle cream to be distributed in the participating 
countries will meet all applicable requirements of those countries.  
5.1.2. Storage 
All study drugs must be stored in a secure environmentally controlled and monitored (manual or 
automated) area in accordance with the labeled storage conditions, with access limited to the 
Investigator and authorized site staff. 
5.1.3. Handling  and Disposal 
Under normal conditions of handling and administration, study drug is not expected to pose 
significant safety risks to site staff .  In the case of unintentional occupational exposure notify the 
monitor, Medical Monitor and/or the Sponsor study contact. 
A Material Safety Data Sheet (MSDS)/equivalent document describing occupational hazards and 
recommended handling precautions either will be provided to the Investigator, where this is required by [CONTACT_1207], or is available upon request from the Sponsor.  
Arrangements will be made for used and unused drug supplies to be returned to the Sponsor or Sponsor designee, or for destruction on site following acceptable, documented procedures.  Further g uidance and information for final disposition of unused study drug will be  provided. 
5.1.4. Preparation  
No special preparation of study drug is required. 
Tapi[INVESTIGATOR_402197] -505-3001  
Dermavant Sciences GmbH.  Clinical Study Protocol – Version 2.0  
Confidential  Page | 36 5.1.5. Administration of Study Drug 
Study drug will be dispensed to subjects at the clinical site in appropriately labeled tubes . 
Subjects will take the tubes home and self- administer study drug (or have caregiver apply if 
necessary), except on clinic visit days (when study drug is applied under supervision at the site), 
to affected areas once daily . 
Subjects will be instructed to apply study drug as follows: 
• Once daily application to affected areas ; subjects are to choose the application time 
they prefer and to apply the study drug at that approximate time each day of study 
participation .  
• If a subject misses a daily dose, it will be recorded as a protocol deviation. The 
subject should continue dosing the next day and should not apply more than once daily to make up for the missed dose on the previous day. 
• If chosen application time is in the evening, the dose should be applied at least 
30 minutes prior to bedtime . 
• Study drug should be applied to dry, clean skin . 
• Wash hands after application, unless treating lesions on the hands or fingernails. 
• Study drug should be applied to all  lesions, including newly appearing lesions and 
lesions that have improved during the study. 
• Subjects are allowed , but not required, to treat fingernails, toenails, palms, soles, and  
scalp lesions with study drug; however, efficacy analyses will not include assessment of improvem ent of psoriasis in these areas .  If using study drug on the scalp , no other 
treatment for scal p psoriasis is permitted during the study. 
• If there is residual cream visible on the disease- affected  lesional  skin, then the subject 
should be instructed to continue to lightly rub the cream into the skin until it is no 
longer visible. 
• If study drug is applied to the subject by [CONTACT_19015], that person should thoroughly wash his/her hands after application.  When possible, use of disposable gloves is recommended. 
• Subject s should record the time of study drug application in the daily diary. 
• Subject s should avoid swimming, bathing, showering, or strenuous activities for at 
least 2  hours after application of study drug. 
• On clinic visit days, study drug should be applied in the clinic under the supervision of site personnel and after safety and efficacy assessments have been completed  
NOTE :  The time of the dose and assessments on clinic visit days will depend on the 
time of the clinic visit.  Therefore, the timing of the clinic visit may differ from the 
subject’s chosen dosing time. The intention is to allow flexibility to accommodate subjects’ schedules.  
Subjects will be instructed/reminded on how to apply study drug at each clinic visit ( except 
during the final treatment visit).  
Tapi[INVESTIGATOR_402197] -505-3001  
Dermavant Sciences GmbH.  Clinical Study Protocol – Version 2.0  
Confidential  Page | 37 5.2. Randomization/Treatment Assignment  
For the double-blind, vehicle-controlled phase of the study, subjec ts will be randomized at a ratio 
of 2:1 to receive tapi[INVESTIGATOR_191753] , 1% or vehicle cream as follows:  
Randomization in Double -Blind, Vehicle -Controlled Phase  
Regimen  Num ber of Subjects  
Tapi[INVESTIGATOR_191753] , 1% once daily for 12 weeks  Approximately 333 Subjects  
Vehicle cream once daily for 12  weeks  Approximately 167 Subjects  
 
Randomization will be stratified by [CONTACT_402253] (PGA scores of 2 and 4, respectively) will be limited to approximately 10% each of the 
total randomized population, and the majority of the enrolled subjects (approximately 80%) will 
have a PGA score of 3, s ignifying moderate disease.   
The randomization lists will be generated using a validated system, which involves a pseudo-random number generator so that the resulting treatment will be both reproducible and non-predictable.  Access to the codes will be co ntrolled and documented. 
5.3. Blinding  
The Investigator, study center staff, subject , and Sponsor will be blinded to treatment 
assignment. 
The study blind should not be broken except in medical emergencies when the appropriate 
management of the subject requires knowledge of the study drug the subject received.  The 
following conditions will apply for breaking the blind: 
• The Investigator or treating physician may unblind a subject’s treatment assignment 
only in the case of an emergency  OR in the event of a serious medical condition 
when knowledge of the study drug is essential for the appropriate clinical management or welfare of the subject as judged by [CONTACT_737]. 
• Investigators have direct access to the system for unblinding an individual study subject . 
• The Investigator should make every effort to first contact [CONTACT_941] M edical Monitor or 
appropriate study personnel to discuss options before unblinding the subject ’s 
treatment assignment.  
• If the Sponsor personnel are not contact[CONTACT_222201], the Investigator 
must notify the Sponsor as soon as possible after unblinding, but without revealing 
the treatment assignment of the unblinded s ubject , unless that information is 
important for the safety of subjects currently in the study. 
• The date and reason for the unblinding must be fully documented in the CRF. 
• A subject  will be withdrawn if the subject’s treatment code is unblinded by [CONTACT_402254].  The primary reason for discontinuation (the event 
or condition which led to the unblinding) will be recorded in the source documents 
and e CRF . 
• The Sponsor or their designee may unblind the treatment assignment for any subject 
with an SAE .  If the SAE requires that an expedited regulatory report be sent to one 
Tapi[INVESTIGATOR_402197] -505-3001  
Dermavant Sciences GmbH.  Clinical Study Protocol – Version 2.0  
Confidential  Page | [ADDRESS_506863]’s treatment 
assignment, may be sent to Investigators in accordance with local regulations. 
5.4. Compliance with Study Drug  Administration  
At baseline, study staff will provide the subject with detailed instructions concerning protocol 
requirements and use of study drug.  Additionally, subjects will be asked to complete a daily 
diary with the time of each application of study drug.  At each post  baseline study visit, study 
staff will review use of study drug, as applicable, with the subject. 
When subjects are dosed at the site, they will apply the study drug under supervision of the study 
staff.  The date and time of each dose administered in the clinic will be recorded in the source 
documents.  The study drug and study subject identification will be confirmed at the time of 
dosing by a member of the study site staff other than the person dispensing the study drug. 
At the time of dispensing study drug to each subject, site personnel will weigh the tubes to be 
dispensed and will record the weight of all tubes dispensed at each visit in the drug accountability logs.  Subjects will be instructed to bring all used and unused tubes with them to 
each study visit.  Site personnel will weigh the returned tubes (used and unused) and record the 
weight in the drug accountability logs.  If a tube has been lost, discarded, or forgotten by [CONTACT_423], then the site personnel will make a notation of this on the drug accountability logs.  The 
site personnel will remind the subject to keep all tubes of study drug dispensed and to bring all 
used and unused tubes to each clinic visit.  These data will be used to estimate subject compliance with use of study drug.  Tubes of study medication dispensed at the most recent prior 
visit which remain unopened (the foil cap on the tube remains fully intact/undisturbed) may be 
re-dispensed to study subjects at the current visit.  Opened, partially used tubes or tubes with foil 
overlay removed are not to be re-dispensed to study subjects.  If there is any question as to re-dispensation, sites should issue new tubes of study medication to the subject(s). 
5.5. Treatment after the End of the Study  
Subject s will not receive any additional treatment with the study drug from the Sponsor after 
completion of the study (with  the exception of eligible subjects who enroll in the separate 
open-label, long-term study) because the indication being studied is not life threatening or seriously debilitating and other treatment options are available.
 
The Investigator is responsible for ensuring that consideration has been given to the poststudy 
care of the subject’s medi cal condition, whether or not the Sponsor is providi ng specific 
poststudy drug. 
5.6. Prior and Concomitant Therapy  
Any medication (including over the counter or prescription medication, vitamins and/or herbal supplements ) administered to the subject up to [ADDRESS_506864] also include name [CONTACT_11889] (generic name, as a 
general rule), dose, frequency, administration routes, and dates of the first and last dose, as applicable.  
The Medical Monitor should be contact[CONTACT_31182]. 
Tapi[INVESTIGATOR_402197] -505-3001  
Dermavant Sciences GmbH.  Clinical Study Protocol – Version 2.0  
Confidential  Page | 39 5.6.1. Permitted Medications and Non drug Therapi[INVESTIGATOR_402227] (Week  12) and that the medication is 
not a prohibited medication as described in the Exclusion Criteria ( Section  4.3). 
In the event of skin infection, topi[INVESTIGATOR_402228];  
however , study drug must not be applied to the area until the skin infection is healed. 
Subjects may use nonmedicated shampoos (must not contain corticosteroids, vitamin D analogs, 
salicylic acid, or coal tar) . 
Nonmedicated emollients may be used on nonlesional skin; emollients should not be applied to lesional skin during treatment and should not be applied on the morning of clinic visits.  The same emollient should be used throughout the subject’s participation in the study. 
Note :  Any emollient used during the study must be recorded as a concomitant medication . 
5.6.2. Prohibited Medications  and Nondrug Therapi[INVESTIGATOR_402229]: 
• Biologic agents:  rituximab, ustekinumab, secukinumab, golimumab, ixekizumab, infliximab, adalimumab, alefacept, etanercept (list is not exclusive, contact [CONTACT_191837]) 
• Systemic treatments :  cyclosporin, interferon, methotrexate, apremilast, tofacitinib, 
mycophenolate, thioguanine, hydroxyurea, sirolimus, azathioprine, other systemic 
immunosuppressive or immunomodulating agents, fumaric acid derivatives, 
vitamin  D3 and analogs (> 5,000 IU/day) , retinoids (eg, acitretin, isotretinoin), 
psoralens, corticosteroids, or adrenocorticotropic hormone analogs 
• Ultraviolet light :  therapy or prolonged exposure to natural or artificial sources of 
UV radiation (eg, phototherapy, tanning beds/booths, or therapeutic sunbathing).  When prolonged exposure cannot be avoided, use of sunscreen products (except on psoriasis plaques) and protective apparel are recommended . 
• Topi[INVESTIGATOR_12969] :  corticosteroids, antihistamines, immunomodulators, anthralin 
(dithranol), Vitamin D derivatives (eg, calcipotriene, calcipot riol), retinoid s (eg, 
tazarotene), or coal tar  
• Drugs known to possibly worsen psoriasis (unless on a stable dose for > 12 weeks) :  beta blockers (eg, propranolol), lithium, iodides, 
angiotensin-converting enzyme inhibitors, and indomethacin 
• Immunization s:  live, attenuated vaccines (inactivated or subunit vaccines are 
acceptable when required)  
• Other:  any investigational products or procedures 
Tapi[INVESTIGATOR_402197] -505-3001  
Dermavant Sciences GmbH.  Clinical Study Protocol – Version 2.0  
Confidential  Page | 40 6. STUDY ASSESSMENTS AN D PROCEDURES  
Study procedures and assessments are summarized in the Schedule of Assessments and  in 
Section  7.  Adherence to the study design requirements, including those specified in the Schedule 
of Assessments ( Table 1 ) are essential and required for study conduct.  Protocol waivers or 
exemptions are not allowed, except for immediate safety concerns . 
6.1. Demography, Medical History, and Baseline Characteristics  
6.1.1. Demographics  
Demographic information collected will include age, sex, race, and ethnicity. 
6.1.2. Medical History  
Medical history  will be collected to ensure subjects are eligible for participation in the study (per 
inclusion Section  4.2 and exclusion Section  4.3 criteria) . 
Data collected will include  year of plaque psoriasis diagnosis, CV medical history and risk 
factors (including height, weight, blood pressure, smoking history, medical conditions, and 
family history of premature CV  disease ) and family history of liver disease. 
6.1.3. Baseline Characteristics  
Single 12- lead E CGs will be obtained using an ECG machine that automatically calculates the 
heart rate and measures PR, QRS, QT, and QTc intervals .  Subjects should be in a supi[INVESTIGATOR_47342] -supi[INVESTIGATOR_21683] 5 m inutes before ECG is measured.  
The Hospi[INVESTIGATOR_5620] (HADS) will be used to evaluate the subject for 
symptoms of depression and anxiety at Screening .  An example of the HADS questionnaire is 
provided in Appendix 1.  
6.2. Efficacy A ssessments 
To minimize inter -observer variability, Investigators and evaluators/raters will be trained on each 
of the required assessments during an Investigator meeting, site initiation visit, and/or utilizing 
online assessments before enrolling subject s at their study center.  Only trained evaluators/raters 
are permitted to perform the efficacy assessments .  To the fullest extent possible, the same 
Investigator (or designated evaluator/rater) will perfor m all efficacy assessments for an 
individual subject  throughout the study.  If it is not possible for the same evaluator/rater to 
continue performing assessments, it is recommended that the primary and subsequent evaluator/rater both examine and discuss their respective scoring during at least 1 visit.  
6.2.1. Assessments Completed by [CONTACT_10670] 
[IP_ADDRESS]. Physician Global Assessment  
The PGA will be  used to assess the primary endpoint in this study.  The PGA is a clinical tool for 
assessing the current state/severity of a subject ’s psoriasis at a given timepoint.  It is a static 
5-point morphological assessment of overall disease severity, as determined by [CONTACT_737], using the clinical character istics of erythema, scaling, and plaque thickness/elevation as 
guidelines ; higher PGA scores represent more severe disease.  The BSA affected is not 
Tapi[INVESTIGATOR_402197] -505-3001  
Dermavant Sciences GmbH.  Clinical Study Protocol – Version 2.0  
Confidential  Page | 41 considered in scoring of the PGA (see Section  [IP_ADDRESS] for details on BSA scoring).  Variations of 
the PGA are frequently used in clinical studies because it is a simple assessment that is more 
similar to the assessments actu ally used in clinical practice (see Appendix 2  for details ).  The 
PGA should be performed first, prior to %BSA  and PASI  assessments.  
[IP_ADDRESS]. Body Surface Area  Affected  
The assessment of the %BSA affected is an estimate of the percentage of total involved skin with 
psoriasis.  For the purpose of clinical estimation, the total palmar surface of the subject’s palm  
and digits  may be assumed to be approximately equivalent to 1% BSA .  The %BSA affected by 
[CONTACT_191838] (from 0 % to 100%).  Details on calculation of approximate % BSA 
involvement in each subject  (total and individual are provided in Appendix 3) .  Percentage BSA 
is a static assessment made without reference to previous scores .   
Note : at screening, baseline , and for all efficacy assessments,  lesions on the subject’s scalp, 
palms, fingernails, toenails, and s oles will not be included in the calculation of %BSA affected as 
these areas will be excluded from the efficacy analyses .   
[IP_ADDRESS]. Psoriasis Area and Severity Index  
The PASI scoring s ystem is a widely -used standard clinical tool for assessing the severity of 
psoriasis that takes into account the overall severity of erythema (redness), induration (plaque thickness), and scale, and the extent of %BSA affected with psoriasis.  The 3 clinical signs are 
each graded on a 5 -point scale ( 0 to 4) and the %BSA affected is scored on a 7- point scale 
(0 to 6) for each of the 4 specified body regions (head, upper extremities, trunk, and lower 
extremities) .  The individual scores are multiplied by a weighted factor for each body region; the 
sum of these scores gives the overall PASI score.  Higher scores indicate more severe disease.  
PASI is a static assessment made without reference to previous scores .  Details on P ASI 
calculation are provided in Appendix 3. 
6.2.2. Assessments Completed by [CONTACT_27720]  
[IP_ADDRESS]. Dermatology Life Quality Index 
Subjects will complete the DLQI questionnair e.  The DLQI is simp le dermatology- specific 
10-question validated questionnaire to assess the impact of the disease on a subject’s quality of 
life (Cardiff University, Department of Dermatology, Quality of Life Questionnaires).  The 
DLQI has become an impo rtant outcome measure in dermatology clinical trials and is the most 
frequently used instrument in studies of randomized controlled trials in dermatology [Basra,  2015] .  The DLQI can be analyzed as a total score (where a higher score indicates greater  
impa irment in quality of life) and can also be scored for the following dimensions:  Symptoms 
and Feelings (items 1 and 2), Daily Activities (items 3 and 4), Leisure (items 5 and 6), Work and 
School (item 7), Personal Relationships (items 8 and 9), and Treatment (item 10).  An example of this assessment is provided in Appendix 4. 
[IP_ADDRESS]. 36−Item Short Form Survey 
The SF -36 is a self -administered questionnaire about physical functioning, bodily pain, role 
limitations due to physical health or personal or emotional problems, emotional well-being, 
social functioning, energy/fatigue, general health perceptions, and perceived change in health 
[Maruish, 2011] .  Eight domain scores and 2 summary component (physical and mental) scores 
Tapi[INVESTIGATOR_402197] -505-3001  
Dermavant Sciences GmbH.  Clinical Study Protocol – Version 2.0  
Confidential  Page | 42 can be calculated; higher scores represent better health status .  This study will use the RAND 
SF-36 Version 1.0.  An example of this assessment is provided in Appendix 5. 
[IP_ADDRESS]. Psoriasis Symptom Diary 
The Psoriasis Symptom Diary is a 16- item (24 -hour reca ll) assessment that measures self -reports 
of psoriasis symptoms, and impact on functional health [ Lebwohl 2014; Strober, 2013; Strober, 
2016].  The participant will complete the diary at the study site at each in -office visit.  The 
severity and bother of psoriasis - related itching, stinging, burning, pain, and scaling and impact 
items about the embarrassment, avoidance of activities with other people, and movement 
restrictions are assessed .  Each item is rated on a [ADDRESS_506865].  
An example of this assessment is provided in Appendix 6. 
[IP_ADDRESS]. Peak Pruritus -Numeric Rating Scale 
The Peak P ruritus -NRS is used to quickly assess itch/pruritus severity over a 24-hour period.  
The subject will utilize the scale to assess peak pruritus  once daily and record  the results in their 
daily diaries . On clinic visit days, the Peak- Pruritis NRS will be assessed in the clinic and not 
recorded in the diary.  An example of the P eak Pruritus-NRS is provided in Appendix 7. 
6.2.3. Optional Clinical Photography 
Clinical photography may be performed in a subgroup of subjects at selected study centers that 
possess the capabilities .  This is not required of subjects for participation in the study.  Informed 
consent/assent and photographic release will be required.  The photographs may not be referred 
to by [CONTACT_191864]. 
Photographs will be taken of a representative area  of the subject’s disease area at t he time points 
specified in the Schedule of Assessments ( Table 1 ; see also Section  7).  Three photographs of the 
selected skin area will be taken  in a standardized fashion (ie, same camera, angle, background, 
distance) .  Procedures for the clinical photography will be contained in the Study Reference 
Manual  or Photography Manual. 
6.3. Safety Assessments  
6.3.1. Adverse Events  
All AEs will be collected from the time the subject signs the ICF until the final visit/contact [CONTACT_191839] .  Additional safety information, including the definition of an AE and the methods for 
recording, evaluating, and assessing causality of AEs and the procedures for completing and transmitting SAE reports are provided in Section  8. 
6.3.2. Brief Physical Exam ination  
A brief physical examination will include, at a minimum, assessments of the skin, lungs, CV  
system, and abdomen (liver and spleen).  Height and weight will be measured at screening  only.  
Investigators should pay special attention to clinical signs related to previous serious illness.  
Tapi[INVESTIGATOR_402197] -505-3001  
Dermavant Sciences GmbH.  Clinical Study Protocol – Version 2.0  
Confidential  Page | 43 6.3.3. Vital Signs  
Vital signs will be measured before blood collection for clinical laboratory assessments and PK 
analysis (where applicable) and will include measurement s of systolic and diastolic blood 
pressure , pulse rate, and body temperature .  Subjects should be in a seated  position for at least 
[ADDRESS_506866] be conducted in accordance with the Study 
Reference Manual  or Laboratory Manual  and the protocol Schedule of Assessments ( Table 1) .  
Laboratory requisition forms must be completed, and samples must be clearly labeled  with the 
subject  number, protocol number, site/center number, and visit date.  Details for the preparati on 
and shipment of samples will be provided by [CONTACT_402255].  Reference ranges for all safety parameters will be 
provided to the site by [CONTACT_402256] s. 
A list of clinical laboratory tests and parameters is provided in  Table 3.  
All laboratory tests with values that are considered clinically significantly abnormal during 
participation in the study should be repeated until the values return to normal or baseline.  If such 
values do not return to normal within a period judged reasonable by [CONTACT_737], the etiology should be identified, if possible, and the Sponsor notified. 
Tapi[INVESTIGATOR_402197] -505-3001  
Dermavant Sciences GmbH.  Clinical Study Protocol – Version 2.0  
Confidential  Page | 44 Table 3: Laboratory Tests 
Diagnostic Screening Tests  
• HBsAg  
• Hepatitis C antibody 
• Anti-HBc • Pregnancy t ests:  (serum at Screeni ng and urine at other visits; 
women of CBP only)  
• FSH (as needed in women of non- CBP only ) 
• At the Investigator’s discretion, subjects may be screened for 
alcohol and illicit drug use.  
Serum Chemistry  
• BUN  
• Creatinine  
• Glucose (fasting not required) 
• Sodium 
• Potassium  
• Chloride • Total carbon dioxide 
• Calcium  
• AST  
• ALT  
• Alkaline phosphatase  • Uric acid  
• Total bilirubin (+fractionated if required)  
• Total protein  
• Albumin 
Hematology  
• Platelet count 
• RBC count 
• WBC c ount (absolute) 
• Reticulocyte count 
• Hemoglobin  
• Hematocrit  • RBC Indices : 
• MCV 
• MCH 
• MCHC  
• Reticulocyte percentage • WBC Differential : 
• Neutrophils 
• Lymphocytes 
• Monocytes 
• Eosinophils 
• Basophils 
Urinalysis  
• Specific gravity  
• Microscopic examination (if blood or protein is abnormal  • Dipstick :  pH, Glucose, 
Protein , Blood Ketones  
ALT  = alanine aminotransferase; Anti -HBc = anti -hepatitis B core antigen; AST  = aspartate aminotransferase; 
BUN  = blood urea nitrogen; CBP  = child -bearing potential; FSH = follicle- stimulating hormone; HBsAg = hepatitis 
B surface antigen;  MCH  = mean corpuscular hemoglobin; MCHC  = mean corpuscular hemoglobin concentration; 
MCV  = mean corpuscular volume; RBC  = red blood cell(s); WBC  = white blood cell (s). 
 
6.3.5. Local Tolerability Scale 
At each specified study visit, the Investigator (or qualified evaluator) will assess the presence 
and overall degree of irritation at the application sites, according to the LTS (an example of the 
LTS is provided in Appendix 8) .  The score will ideally represent an “average” across all 
application sites .  To the fullest extent possible, the same Investigator (or designated evaluator) 
will perform all tolerability a ssessments for an individual subject throughout the study.  If the 
subject  is applying study treatment to “sensitive areas” (eg, genitals, face, neck, and skin folds), 
then the degree of irritation for these areas should also be assessed by [CONTACT_093]. 
Additionally, at each specified study visit, the participant will use a 5 -point LTS to assess the 
presence and degree of burning/stinging and itching at the treatment areas.  The score will ideally 
represent an “average ” across all application sites . 
Tapi[INVESTIGATOR_402197] -505-3001  
Dermavant Sciences GmbH.  Clinical Study Protocol – Version 2.0  
Confidential  Page | [ADDRESS_506867] will be considered  an 
overdose.  Ingestion of a 30-gram tube of tapi[INVESTIGATOR_191753] , 1% would result in an oral dose of 
300 mg. 
The Sponsor does not recommend specific treatment for an overdose; however, in the event of an 
overdose, the Investigator (or treating physician) should do the following: 
• Contact [CONTACT_191841] 
• Closely monitor the subject for AEs/SAEs and laboratory abnor malities  
• Provide general symptomatic treatment as necessary  
• Document the quantity of the excess dose as well as the duration of the overdosing in the eCRF.  
• If the Medical Monitor requests a plasma sample for PK analysis, then a blood sample for PK should be obtained within [ADDRESS_506868].  
6.5. Pharmacokinetics  
A single blood sample for PK analysis of tapi[INVESTIGATOR_191753] , 1% will be collected at a subset of 
sites in a subset of subjects at timepoints indicated in the Schedule of Assessments ( Table 1)  and 
Section  7.  The actual date and time of each blood sample collection will be  recorded as well as 
the date and time of the last dose of study drug prior to sample collection .  Collection, 
processing, storage, and shippi[INVESTIGATOR_402230]. 
Concentrations of tapi[INVESTIGATOR_191752] w ill be determined in plasma samples using a validated  bioanalytical 
method.  Raw data will be archived at the bioanalytical site . 
Tapi[INVESTIGATOR_402197] -505-3001  
Dermavant Sciences GmbH.  Clinical Study Protocol – Version 2.0  
Confidential  Page | 46 7. TIMING OF PROCEDURES  AND ASSESSMENTS  
This section lists the procedures and assessment to be performed at scheduled timepoints during 
the study as outlined in the Schedule of Assessments ( Table 1) .  Information on study procedures 
and assessment s is provided in Section  6. 
• Any change in timing or any addition of a timepoint(s) for any planned study 
assessment must be documented in a “Note to File,”  which is approved by [CONTACT_191844]; this will NOT constitute a protocol amendment.  
• The IRB/IEC will be informed of any safety issues that require alteration of the safety monitoring scheme or amendment of the Informed Consent Form (ICF). 
NOTE :  Assessments and procedures should be performed predose on clinic visit days. 
7.1. Visit 1; Screening Period (Day -34 t o Day -1) 
After the subject has signed the Informed Consent Form (ICF ), potential study subjects will 
undergo Screening procedures and assessments to confirm eligibility to participate in the study .  
Screening assessments will include the following: 
• Demography recording 
• Serum pregnancy test (females of child -bearing potenti al) 
• Medical history recording 
• ECG recording  
• Brief physical exam ination (including weight, height, and body masss index [ BMI ]) 
• Vital signs measurements  
• HADS  assessment  
• PGA score  
• %BSA affected calculation ; subject’s scalp, palms, and soles should be excluded 
from the %BSA calculations used to determine patient’s eligibility  
• Blood sample collection for clinical laboratory tests (serum chemistry, hematology, diagnostic tests)  
• Urinalysis  
• AE recording (from the time the ICF is signed) 
• Concomitant medication recording (from the time ICF is signed) 
To determine subject eligibility at Screening, a single repeat of tests or procedures may be allowed at the discretion of the Investigator .  The  Medical M onitor should be consulted if 
needed . 
 
Tapi[INVESTIGATOR_402197] -505-3001  
Dermavant Sciences GmbH.  Clinical Study Protocol – Version 2.0  
Confidential  Page | 47 7.2. Visit 2; Baseline  (Day 1) 
On Day 1, subjects will be reassessed to confirm continued eligibility  to participate in the study .  
All subjects who continue to meet study eligibility criteria will be randomized  to treatment. 
The following additional procedures and assessments will be performed  at the Baseline Visit: 
• Urine pregnancy test (females of child -bearing potential) 
• Changes to medical history will be recorded 
• Brief physical examination  
• Vital signs measurement  
• Photography of a representative area of the subject’s disease area (optional; at a 
subsection of study sites) 
• PGA score  
• %BSA affected calculation  (performed before PASI); s ubject’s scalp, palms, and 
soles should be excluded from the %BSA calculations used to confirm  patient’s 
eligibility  
• PASI  
• DLQI  
• SF-36 
• PSD 
• Peak P ruritus -NRS  
• AE recording  
• Concomitant medication recording (from the time ICF is signed ) 
• Diary  dispensed (subjects will be instructed in how and when to complete diary) 
• Subject randomized to study treatment and registered in IVRS 
• Study drug dispensed 
• Instruction on how to apply  study drug 
• Study drug application under supervision 
7.3. Double -Blind, Vehicle -Controlled Phase  
Subjects will return to the stud y site at Weeks 2, 4, 8 , and 12 and will be contact[CONTACT_402257] 6 and 10 of the double-blind phase of the study. 
7.3.1. Visit 3; Week  2 (Day 15 ±2 Days) 
The following procedures and assessments will be performed at Visit 3: 
• Vital signs  
• PGA score  
• %BSA affected  calculation (performed before PASI)  
• PASI  
• LTS 
• PSD 
Tapi[INVESTIGATOR_402197] -505-3001  
Dermavant Sciences GmbH.  Clinical Study Protocol – Version 2.0  
Confidential  Page | 48 • Peak P ruritus -NRS  
• AE recording  
• Concomitant medication recording 
• Collect and dispense subject diaries  
• Review subject diaries for treatment compliance  
• Collect and dispense study drug 
• Review instructions on how to apply study drug 
• Study drug application under supervision 
7.3.2. Visit 4 ; Week  4 (Day 29 ±2 Days) 
The following procedures and assessments will be performed at Visit 4: 
• Urine pregnancy test (females of child -bearing potential) 
• Brief physical examination  
• Vital signs measurement  
• Photography of a representative area of the subject’s disease area (optional; at a 
subset of study sites) 
• Blood sample collection for PK analysis (subset of sites and subjects ) 
• Blood sample collection for clinical laboratory tests  
• PGA score  
• %BSA affected calculation (performed before PASI ) 
• PASI  
• LTS 
• DLQI  
• SF-36 
• PSD 
• Peak P ruritus -NRS  
• AE recording  
• Concomitant medication recording 
• Collect and dispense subject diaries  
• Review subject diaries for treatment compliance  
• Collect and dispense study drug 
• Review instructions on how to apply study drug 
• Study drug application  under supervision 
7.3.3. Visit 5 ; Week  8 (Day 57 ±2 Days) 
The following procedures and assessments will be performed at Visit 5: 
• Urine pregnancy test (females of child -bearing potential) 
• Brief physical examination  
Tapi[INVESTIGATOR_402197] -505-3001  
Dermavant Sciences GmbH.  Clinical Study Protocol – Version 2.0  
Confidential  Page | 49 • Vital signs measurement  
• Photography of a representative area of the subject’s disease area (optional; at a 
subset of study sites only) 
• PGA score  
• %BSA affected calculation (performed before PAS I) 
• PASI  
• LTS 
• PSD 
• Peak P ruritus -NRS  
• AE recording  
• Concomitant medication recording 
• Collect and dispense subject diaries  
• Review subject diaries for treatment compliance  
• Collect and dispense study drug 
• Review instructions on how to apply study drug 
• Study drug application under supervision 
7.3.4. Visit 6 ; Week  12 (Day 85 ±2 Days) 
The following procedures and assessments will be performed at Visit 6: 
• Urine pregnancy test (females of child -bearing potential) 
• Brief  physical examination  
• Vital signs measurement  
• Photography of a representative area of the subject’s disease area (optional, at a 
subsection of study sites) 
• Blood sample collection for PK analysis (subset of sites and subjects ) 
• Blood sample collection for clinical laboratory tests  
• PGA score  
• %BSA affected calculation (performed before PASI)  
• PASI  
• LTS 
• DLQI  
• SF-36 
• PSD 
• Peak P ruritus -NRS  
• AE recording  
• Concomitant medication recording 
• Collect subject diaries  
• Review subject diaries for treatment compliance  
Tapi[INVESTIGATOR_402197] -505-3001  
Dermavant Sciences GmbH.  Clinical Study Protocol – Version 2.0  
Confidential  Page | 50 • Collect study drug  
7.3.5. Phone Contact [CONTACT_328548] 6 ( Day 43 ±2 Days) and 10 ( Day 71 ±2 Days) 
Subjects will be contact[CONTACT_222209] [ADDRESS_506869] AEs and concomitant medication use.  Subjects should be reminded to 
complete their daily diary and bring it with them to the next clinic visit.  
7.4. Follow- Up Visit 7; Week  16 (Day 113 ±4 D ays) 
Subjects who do not enroll in the open- label  long- term study will return to the study site at 
Week  16 to complete follow- up assessments as follows:  
• Urine pregnancy test (females of child -bearing potential) 
• Brief physical examination  
• Vital signs measurement  
• Blood sample collection for clinical laboratory tests  
• Urinalysis  
• PGA score  
• %BSA  affected calculation (performed before PASI)  
• PASI  
• LTS 
• DLQI  
• SF-36 
• PSD 
• Peak P ruritus -NRS  
• AE recording  
• Concomitant medication recording 
7.5. Early Termination Visit  
Subjects who withdraw early from the study will be asked to return to the study site to complete Early Termination assessments as follows: 
• Urine pregnancy test (females of child -bearing potential) 
• Brief physical examination  
• Vital signs measurement  
• Blood sample collection for clinical laboratory tests  
• Urinalysis  
• PGA score  
• %BSA affected calculation (performed before PASI)  
• PASI  
• LTS 
• DLQI  
Tapi[INVESTIGATOR_402197] -505-3001  
Dermavant Sciences GmbH.  Clinical Study Protocol – Version 2.0  
Confidential  Page | 51 • SF-36 
• PSD 
• Peak P ruritus -NRS  
• AE recording  
• Concomitant medication recording 
• Collect subject diaries  
• Review subject diaries for treatment compliance  
• Collect study drug 
7.6. End of Study  
The end of study is defined as when the last active subject has completed the Week  16 Follow-up 
Visit 4 weeks after the end of treatment (if subject does not enroll in the separate long- term 
study) OR the last active subject has completed the 12 w eeks of treatment in this study (if subject 
is eligible and enrolls in the separate long-term study). 
Tapi[INVESTIGATOR_402197] -505-3001  
Dermavant Sciences GmbH.  Clinical Study Protocol – Version 2.0  
Confidential  Page | [ADDRESS_506870] ( AESI s).  At each 
visit/contact, subjects should be questioned in a general way so as not to introduce bias in detecting AEs and/or SAEs.  O pen-ended  and non-leading verbal questioning of the subject is 
the preferred method to inquire about AE occurrence. 
Investigators are not obligated to actively seek AEs or SAEs in former study subject s.  However, 
if the Investigator learns of any SAE, including a death, at any time  after a subject  has been 
discharged from the study, and he/she considers the event reasonably related to the study drug or 
study participation, the Investigator should promptly notify the Sponsor. 
8.1.1. Definition of Adverse Events  
An AE is a ny untoward medical occurrence in a Subject  temporally  associated with the use of a 
medicinal product, whether considered causally  related or not related to the medicinal product. 
An AE can therefore be any unfavorable and unintended sign (including an abnormal laboratory 
finding), symptom, or disease (new or exacerbated) temporally associated with t he use of a 
medicinal product. 
Events meeting the definition of an AE include : 
• Any abnormal laboratory test results (hematology, clinical chemistry) or other safety 
assessments ( eg, vital signs measurements), including those that worsen from 
baseline, and felt to be clinically significant in the medical and scientific judgment of 
the Investigator 
• Exacerbation of a chronic or intermittent pre-existing condition (eg, at opic dermatitis) 
including either an increase in frequency and/or intensity of the condition 
− For skin-related AEs, it should be noted whether or not the event is in the area of 
active application of study drug, and/or if spreading beyond the application si te. 
• New conditions detected or diagnosed after study drug administration even though it 
may have been present prior to the start of the study 
• Signs, symptoms, or the clinical sequelae of a suspected interaction 
• Signs, symptoms, or the clinical sequelae of a suspected overdose of either study drug or a concomitant medication (overdose per se will not be reported as an AE/SAE) 
• "Lack of efficacy" or "failure of expected pharmacological action" per se will not be reported as an AE or SAE .  Such instances will be captured in the efficacy 
assessments.  However, the signs, symptoms, and/or clinical sequelae resulting from 
lack of efficacy will be reported as AE or SAE if they fulfill the definition of an AE 
or SAE.  
• Sympt omatic complaints at the site of local application ( eg, burning/stinging, 
pruritus, and erythema) 
Events that do not  meet the definition of an AE include: 
Tapi[INVESTIGATOR_402197] -505-3001  
Dermavant Sciences GmbH.  Clinical Study Protocol – Version 2.0  
Confidential  Page | 53 • Any clinically significant abnormal laboratory findings or other abnormal safety 
assessments that are associated with the underlying disease, unless judged by [CONTACT_152889] ’s condition 
• The disease/disorder being studied or expected progression, signs, or symptoms of the 
disease/disorder being studied, unl ess more severe than expected for the subject’s 
condition 
• Medical or surgical procedure ( eg, endoscopy, appendectomy); the condition that 
leads to the procedure is an AE 
• Situations where an untoward medical occurrence did not occur (social and/or 
convenience admission to a hospi[INVESTIGATOR_307]) 
• Anticipated day -to-day fluctuations of pre-existing disease(s) or condition(s) present 
or detected at the start of the study that do not worsen 
8.1.2. Definition of Serious Adverse Event  
If an event is not an AE per Section  8.1.1, then it cannot be an SAE even if serious conditions are 
met ( eg, hospi[INVESTIGATOR_1080]/symptoms of the disease under study, death due to progression 
of disease, etc.).  
An SAE is any untoward medical occurrence that, at any dose:  
• Results in death  
• Is life -threatening 
− The term “life threatening” refers to an event in which the s ubject was at risk of 
death at the time of the event .  It does not refer to an event, which hypothetically 
might have caused death, if it were more severe.  
• Requires hospi[INVESTIGATOR_1081] 
− In general, signifies that the subject has been detained (usually involving at least 
an overnight stay) at the hospi[INVESTIGATOR_22771]/or 
treatment that would not have been appropriate in the physician’s office or 
outpatient  setting .  Complications that occur during hospi[INVESTIGATOR_1084].  If a 
complication prolongs hospi[INVESTIGATOR_9236], the 
event is serious.  When in doubt as to whether “hospi[INVESTIGATOR_059]” occurred or was necessary, the AE should be considered serious. 
− Hospi[INVESTIGATOR_63336] a pre -existing condition that did not 
worsen from baseline is not considered an AE. 
• Results in disability/incapacity:  a substantial disruption of a person’s ability to 
conduct normal life functions. 
− This definition is not intended to include experiences of relatively minor medical 
significance such as uncomplicated headache, nausea, vomiting, diarrhea, influ enza, and accidental trauma (eg , sprained ankle) which may interfere or 
prevent everyday life functions but do not constitute a substantial disruption. 
• Results in a congenital anomaly/birth defect 
• Medical or scientific judgment should be exercised in deciding whether reporting is appropriate in other situations, such as important medical events that may not be immediately life -threatening or result in death or hospi[INVESTIGATOR_402231] -505-3001  
Dermavant Sciences GmbH.  Clinical Study Protocol – Version 2.0  
Confidential  Page | [ADDRESS_506871] been identified as AEs of particular clinical 
importance and will be reported as AESIs in this study; in each case study drug may  be 
discontinued, based on Investigator judgment, and may be restarted when the event resolves : 
• Contact [CONTACT_8748] :  the study site should collect location, duration, size, associated 
symptoms (itching, burning, pain), severity (mild, moderate, severe), and photograph 
the affected site (if possible).  If the subject contacts the study site to report 
significant skin irritation at o r near the site of study drug application between study 
visits, the subject should be brought in for an unscheduled visit, if possible. 
• Folliculitis :  the study site should collect the location, duration, size, associated 
symptoms (itching, burning, pain), severity (mild, moderate, severe), indicate whether 
pustular, and photograph the affected site (if possible). 
• Headache:  the study site should collect duration, severity (mild, moderate, severe), onset, and location  (e.g., frontal, temporal, occipi[INVESTIGATOR_307], di ffuse). 
Additional AESIs may be identified by [CONTACT_402258].  
For each AESI, a narrative may be written and included in the Clinical Study Report. 
8.2. Classification of Adverse Events  
8.2.1. Assigning Severity Rating for Adverse Events 
[IP_ADDRESS]. Criteria for Determining Averse Event Severity  
The Investigator will make an assessment of  the severity of each AE and SAE according to the 
National Cancer Institute Common Terminology Criteria for Adverse Events (CTCAE), v. 
5.0, 2017.  For terms not specified with the CTCAE, the criteria in  Table 4 should be used to 
determine the grade severity.  
Tapi[INVESTIGATOR_402197] -505-3001  
Dermavant Sciences GmbH.  Clinical Study Protocol – Version 2.0  
Confidential  Page | 55 Table 4: Criteria for Determining the Grade/Severity of Adverse Event Terms Not 
Specified by [CONTACT_163000] l Cancer Institute CTCAE  
Grade Criteria  
1 Mild; asymptomatic or mild symptoms, clinical or diagnostic observations only; intervention not 
indicated  
2 Moderate; minimal, local, or noninvasive intervention indicated; limiting age -appropriate instrumental 
activities of daily livinga 
3 Severe or medically significant but not immediately life -threatening; hospi[INVESTIGATOR_24599]; disabling; limiting self -care activities of daily livingb 
4 Life threatening consequences; urgent intervention indicated  
5 Death related to adverse event  
CTCAE  = Common Terminology Criteria for Adverse Events . 
a  Instrumental activities of daily living refer to preparing meals, shoppi[INVESTIGATOR_3112], using the telephone, 
managing money, etc.  
b Self-care activities of daily living refer to bathing, dressing and undressing, feeding self, using the toilet, taking medic ations, 
and not bedridden.  
 
Adverse event severity should be recorded in the appropriate section of the adverse event case report form and in the subject ’s source documents. 
[IP_ADDRESS]. Toxicity Management Criteria  
[IP_ADDRESS].1. Grade [ADDRESS_506872] study withdrawal/follow-up evaluations completed. 
[IP_ADDRESS].2. Grade [ADDRESS_506873] s who develop a Grade 3 AE should be managed as follows: 
• If the Investigator has compelling evidence that the Grade [ADDRESS_506874], then dosing may continue after discussion with the 
Medical Monitor. 
• Subject s who develop a Grade [ADDRESS_506875] withdrawal study evaluations 
completed.  
[IP_ADDRESS].3. Grade [ADDRESS_506876] 
withdrawal study evaluations completed. 
Tapi[INVESTIGATOR_402197] -505-3001  
Dermavant Sciences GmbH.  Clinical Study Protocol – Version 2.0  
Confidential  Page | 56 [IP_ADDRESS].4. Other Management Criteria : 
The Medical Monitor should be notified if any of the following occur: 
• Severe signs or symptoms, or significant changes in any of the safety assessments, 
that put the s afety of the subject  at risk (eg , laboratory tests or vital signs, etc.) as 
judged by [CONTACT_737]. 
8.2.2. Assigning Causal Relationship to Study Drug 
The Principal Investigator [INVESTIGATOR_402232] .  Causality assessment is not to be 
delegated; however, if delegation is unavoidable due to investigator inaccessibility, this must be 
recorded as a protocol deviation .  The  reasonable possibility of the relationship of an adverse 
event to study drug is to be assessed with careful medical consideration at the time of evaluation 
of an adverse event .  The following definitions are to be used for the relationship of the adverse 
event to study drug: 
• Related :  A clinical event, including laboratory test abnormality, with a temporal 
relationship to study drug administration that makes a causal relationship plausible, 
unlikely attributed to concurrent disease or other drugs or chemicals, and that follows 
a clinically reasonable response on re- administration (rechallenge) or withdrawal 
(dechallenge), although information on drug withdrawal may be lacking or unclear. 
• Not related :  A clinical event, including laboratory test abnormality, with a temporal 
relationship to study drug administration that makes a causal relationship improbable and/or in which other drugs, chemicals, or underlying disease provide a plausible 
explanation. 
Any AEs /SAEs assessed as related  to study participation (eg, protocol-mandated procedures, 
invasive tests, or change in existing therapy) or related to study drug will be recorded from the time a subject consented to participate in the study up to and including any follow-up contact. 
All AEs, whether related to study drug or not, must be fully and completely documented on the 
AE page of the eCRF  and in the s ubject’s clinical record .  In the event a subject  is withdrawn 
from the study because of an AE , the p rimary reason for withdrawal (ie , due to an AE ) must be 
recorded on the e CRF  as such.  
8.3. Time Period and Frequency for Event  Assessment and Follow-Up  
8.3.1. Adverse Event Reporting  
All AEs will be collected from the time of signed informed consent until the final visit.  
Any AEs assessed as related to study participation (eg, protocol-mandated procedures, invasive 
tests, or change in existing therapy) will be collected from the time a subject consented to participate in the study up to and including any follow-up contact. 
All SAEs will be recorded in the eCRF and reported to the Sponsor w ithin 2 4 hours via email or 
phone (refer to Medical Monitor/Sponsor Information page for contact [CONTACT_3031]) (see 
Section  8.4).  
Tapi[INVESTIGATOR_402197] -505-3001  
Dermavant Sciences GmbH.  Clinical Study Protocol – Version 2.0  
Confidential  Page | 57 8.3.2. Follow- Up of Adverse Events  
After the initial AE/SA E report, the Investigator is required to proactively follow each subject at 
subsequent vi sits/contacts .  All SAEs and nonserious AEs will be followed until resolution, until 
the condition stabilizes, until the event is otherwise explained, or until the subject is lost to 
follow-up. 
The Investigator will assess the outcome of each AE using the following criteria: 
• Recovered/Resolved :  The event has improved or subject recuperated.  
• Recovered/Resolved with sequelae:  The subject has recuperated but retained 
pathological conditions resulting from the prior disease or injury. 
• Recovering/Resolving:  The event is improving. 
• Not recovered/Not resolved :  The event has not improved or subject recuperated. 
• Unknown:  The outcome of the event is not known, not observed, not recorded, or 
refused . 
• Fatal:  Termination of life as an outcome of the AE. 
8.4. Reporting Procedures  
8.4.1. Serious Adverse Event Reporting  
When an Investigator determines that an AE meets the protocol definition of an SAE during the 
study, he/she must notify the Sponsor using an SAE Report Form within 2 4 hours of the study 
site personnel’s knowledge of the event , regardless of the Investigator assessment of the 
relationship of the event to study drug.  Relevant information will be entered on the AE page and on all other applicable pages of the eCRF ; source documentation should not be sent with the 
SAE Report Form unless requested . 
Follow-up information  received on SAEs should be faxed to the Sponsor within 1 business day 
of receipt  (refer to Medical Monitor/Sponsor Information page for contact [CONTACT_3031]).  This 
information should be included on a follow-up SAE form and placed with the origina l SAE 
information. 
All SAEs will be followed until resolution, until the condition stabilizes, until the event is 
otherwise explained, or until the subject is lost to follow -up. 
The completed  SAE Report form should be submitted via email or fax to the SAE Reporting 
Contact  [CONTACT_402259]/Sponsor Information Page  of this protocol. 
Do not delay reporting a suspected SAE  in order to obtain additional information.  Any 
additional information, if collected, can be reported as a follow- up to the initial r eport. 
8.4.2. Regulatory Reporting Requirements for Serious Adverse Events  
Prompt notification by [CONTACT_222215] (even for non-interventional post-
marketing  studies) is essential so that legal obligations and ethical responsibilities towa rds the 
safety of subjects and the safety of a product under clinical investigation are met.  
The Sponsor has a legal responsibility to notify both the local regulatory authority and other regulatory agencies about the safety of a product under clinical investigation .  The Sponsor will 
Tapi[INVESTIGATOR_402197] -505-3001  
Dermavant Sciences GmbH.  Clinical Study Protocol – Version 2.0  
Confidential  Page | 58 comply with country-specific regulatory requirements relating to safety reporting to the 
regulatory authority, IRB/IEC, and Investigators.  
Investigator safety reports are prepared for suspected unexpected serious adverse reactions according to local regulatory requirements and are forwarded to Investigators as necessary. 
An Investigator who receives an Investigator safety report describing a SAE(s) or other specific 
safety information ( eg, summary or listing of SAE s) from the Sponsor will file it with the 
Investigator’s Brochure and will notify the IRB/IEC, if appropriate, according to local 
requirements.  
8.5. Pregnancy Management and Reporting  
Any female subject who becomes pregnant during the study will be withdrawn.  Details will be collected for all pregnancies in female subjects and female partners of male subjects that begin 
after the start of dosing and through the Follow-up visit.  Pregnancy is not automatically 
considered an AE. 
If a pregnancy is reported, then the Investigator should complete a Pregnancy Report Form and  
submit via email or fax to the Pregnancy  Reporting Contact [CONTACT_402260]/Sponsor Information Page  of this protocol, within [ADDRESS_506877]  will also be followed to determine the outcome of the 
pregnancy.  Information on the status of the mother and child will be forwarded to the Sponsor.  
Generally, follow-up will be no longer than 6 to 8 weeks following the estimated delivery date.  Any premature termination of the pregnancy will be reported. 
Any SAE occurring in association with a pregnancy brought to the Investigator ’s attention after 
the subject  has completed the study and considered by [CONTACT_402261] ’s repres entative . 
The Investigator must attempt to collect pregnancy information on any female partners of male 
study subject s who become pregnant while the subject  is enrolled in the study.  Pregnancy 
information must be reported to the Sponsor or the Sponsor ’s representative as described above.  
The partner will also be followed to determine the outcome of the pregnancy.  Information on the 
status of the mother and child will be forwarded to Sponsor or the S ponsor ’s representative.  
Generally, follow-up will be no longer than 6 to 8 weeks following the estimated delivery date.  Any premature termination of the pregnancy will be reported  on the pregnancy report form. 
8.6. Safety Oversight  
No independent Data Monitoring Committee will be used for this study; however, the Sponsor (including the Medical Monitor) will monitor safety on a periodic basis throughout the study. 
Tapi[INVESTIGATOR_402197] -505-3001  
Dermavant Sciences GmbH.  Clinical Study Protocol – Version 2.0  
Confidential  Page | [ADDRESS_506878] current version of the 
Medical Dictionary for Regulatory Activities (MedDRA) .  Concomitant medications will b e 
coded with the most current version of World Health Organization Drug Global Dictionary 
(WHODrug  Global). 
The Investigator will retain original source documents and the Sponsor will receive CRF -required data as electronic datasets .  Subject  initials will not be collected or transmitted to 
the Sponsor. 
Tapi[INVESTIGATOR_402197] -505-3001  
Dermavant Sciences GmbH.  Clinical Study Protocol – Version 2.0  
Confidential  Page | 60 10. STATISTICAL CONSIDER ATIONS AND DATA ANAL YSES  
This study will evaluate the efficacy and safety of tapi[INVESTIGATOR_191753], 1% compared with vehicle 
control cream in adults with plaque psoriasis. 
10.1. General Consideration s 
All study data will be summarized by [CONTACT_2070] .  Categorical 
variables will be reported us ing frequency and percentage (eg, gender, race).  Continuous 
variables will be reported using number of patients, mean, standard deviation ( SD), median, 
minimum, and maximu m.  All efficacy  and safety data will be listed by [CONTACT_1130]. 
10.2. Determination of Sample Size  
It is assumed that the proportion of subjects who achieve PGA sco re of clear (0) or almost 
clear  (1) with a minimum 2-grade improvement from Baseline at Week  12 will be 40% for 
subjects receiving tapi[INVESTIGATOR_222182] 15% for subjects receiving vehicle control.  With 500 subjects randomized in a 2:1 ratio (approximately 333 subjects receiving tapi[INVESTIGATOR_191752] c ream , 
1% and approximately [ADDRESS_506879] s receiving vehicle cream)  there will be > 99% power f or a 
statistical significance (2 -sided p< 0.05).  If tapi[INVESTIGATOR_402203] 35%, and vehicle response 
rate is 20%, the power will be > 94%.  The power is calculated from a Fisher Exact sample size calculation which is conservative.  It is assumed that up to 25% of the subjects will be lost to 
follow-up by [ADDRESS_506880] 1 application of study drug will be included in the 
Safety population.  Subjects will be analyzed as treated . 
10.3.2. Intent -To-Treat  
All randomized subjects will be included in the Intent- to-treat (ITT) population.  Subjects will be 
analyzed as randomized. 
10.3.3. Per-Protocol 
All subjects in the ITT population who did not have any major protocol deviations will be 
included in the Per Protocol (PP) population.  Subjects will be analyzed as treated . 
10.3.4. Pharmacokinetic 
All subjects who undergo plasma PK sampling and have evaluable concentration- time data for 
analysis  will be included in the PK population.  A sample that is below the limit of quantification 
(BLQ) of the assay is considered evaluable.  
Tapi[INVESTIGATOR_402197] -505-3001  
Dermavant Sciences GmbH.  Clinical Study Protocol – Version 2.0  
Confidential  Page | 61 10.4. Planned Analyses  
All efficacy and safety measures over the course of the study will be presented .  Details of 
planned analyses will be described in the S tatistical Analysis P lan (SAP) , which will be finalized 
prior to database lock. 
10.4.1. Disposition and Demographics 
Demographic and baseline characteristics as well as medical history will be summarized using 
the ITT population, including frequency and percentages for categorical variables and mean, 
standard deviation, median, minimum, and maximum for continuous variables. 
The numbers of subjects in the different analysis populations will be summarized by [CONTACT_6490], including overall categories. 
10.4.2. Efficacy Analyses 
All efficacy analyses wil l be based on the ITT population and will be repeated for the 
PP population only for the primary and secondary efficacy endpoints as supportive analysis. 
 
[IP_ADDRESS].  Primary Endpoint Analyses  
The primary efficacy endpoint is proportion of subjects who achieve PGA score of clear (0) or 
almost clear (1) with a minimum 2 -grade improvement from Baseline at Week  12.  The primary 
efficacy endpoint will be analyzed using a Cochran–Mantel –Haenszel (CMH ) test stratified by  
[CONTACT_402242] (PGA scores of 2, 3 or 4). 
[IP_ADDRESS]. Secondary and Exploratory Efficacy Endpoint Analyses  
The secondary eff icacy endpoints are as follows:  
• Proportion of subjects with ≥ 75% improvement in PASI from Baseline at Week  12 
• Mean change in %BSA affected from Baseline to Week  12 
• Proportion of subjects with a PGA score of 0 or 1  at Week  12 
• Proportion of subjects with ≥90% improvement in PASI score from Baseline to Week 12 
Exploratory efficacy endpoints are as follows:  
• Time to achieve a PGA score of 0 or 1 with a minimum 2 -grade improvement from 
Baseline 
• Proportion of subjects with a PGA score of 0 or 1 at Weeks 2 , 4, and 8 
• Proportion of subjects who achieve a PGA score of 0 or 1 with a minimum 2 -grade 
improvement from B aseline at Weeks 2, 4, and 8 
• Mean absolute and percent change in PASI score from Baseline to Weeks 2, 4, 8, 
and 12 
• Proportion of subjects with ≥ 50% improvement in PASI score from Baseline to 
Weeks 2, 4, 8, and 12 
• Proportion of subjects with ≥ 75% improvem ent in PASI score from Baseline to 
Weeks 2, 4, and 8 
Tapi[INVESTIGATOR_402197] -505-3001  
Dermavant Sciences GmbH.  Clinical Study Protocol – Version 2.0  
Confidential  Page | 62 • Proportion of subjects with  ≥ 90% improvement in PASI score from Baseline to 
Weeks 2, 4, and 8 
• Mean change in %BSA affected from Baseline to Weeks 2, 4, and 8 
The same methods as discussed for the primary analyses will be used to analyze all dichotomiz ed 
secondary endpoints .  The secondary efficacy endpoints will be tested sequentially in the order 
listed .  Testing will stop if non- significance (2 -sided p ≥ 0.05) is observed. 
Other efficacy endpoints will be analyzed using CMH test for proportions, and analysis of 
covariance ( ANCOVA) model for continuous variables.  CMH tests will be stratified by [CONTACT_402262], and ANCOVA models will include PGA score as a covariate. 
All endpoints will be  summar ized descriptively as follows:  continuous data will include the 
mean, SD, minimum, maximum, median, and number of observations; descriptive summary 
statistics for categorical data will include frequency counts and percentages.  
10.4.3. Safety Analyses 
The Safety P opulation will be used in the analysis of safety data.  Data will be listed by [CONTACT_402244] .  No formal statistical comparisons will be made for 
safety data. The number and proportion of subjects with TEAEs  will be summarized by [CONTACT_3148], system 
organ class, and preferred term for all TEAEs , all TEAEs  considered by [CONTACT_303811], all SAEs , and all TEAEs  leading to study drug discontinuation.  
Summaries of AEs will be presented separately for double-blind and open- label treatment 
phases .  All AE summaries will include information for AEs that occurred after administration of 
the first dose of study drug until completion of the final study visit.  Data listings will be 
provided for subjects who discontinued the study due to an AE  and for subjects with an SAE. 
Selected laboratory data will be analyzed using descriptive summary statistics  and will be 
presented by [CONTACT_126215], including the number of non-missing observations, mean and SD, median, upper and lower quartiles, minimum and maximum for values and 
changes from Baseline.  Categorical safety data will be analyzed using frequency tables and, if 
applicable, shif t tables.  
Vital signs will be listed by [CONTACT_402263]. 
Mean scores from the LTS will be summarized by [CONTACT_765].  
10.4.4. Analysis of Functional Outcomes and Quality of Life Endpoints  
The subject -reported endpoint s to examine the effect of study drug on psoriasis symptom 
severity and the associated impact on daily activities and attitudes are as follows: 
• Change in Peak Pruritus- NRS from Baseline at Weeks 2, 4, 8, and 12
 
• Change over time in psoriasis impact on daily activities, as measured by [CONTACT_402264] 
• Change over time in psoriasis symptoms, as measured by [CONTACT_402239]  
• Change over time in physical component score and mental component score, as 
measured by [CONTACT_20763]-36 q uestionnaire 
Tapi[INVESTIGATOR_402197] -505-3001  
Dermavant Sciences GmbH.  Clinical Study Protocol – Version 2.0  
Confidential  Page | [ADDRESS_506881], day, and time; summaries 
will be presented by [CONTACT_402265]. 
Unless stated otherwise, descriptive summaries for continuous variables will include n, mean, 
SD, median, minimum, and maximum.  If data permit , time to steady state will be assessed using 
the sampled trough values.  Exploratory analyses may include relationships of plasma concentrations with patient demographics or AEs . 
10.5. Interim Analyses 
No interim analyses will be performe d from a statistical standpoint. 
10.6. Handling of Missing Data  
Every effort will be made to collect complete data at all visits.  
The primary method of handling of missing data will utilize Multiple Imputations (MI) .  For 
sensitivity analysis, Treatment Failure (TF) will be imputed for missing data. 
For the MI model, 100 imputations will be generated using PROC MI of SAS.  Fully Conditional 
Specification (FCS) model using the regression method will be used with the response (eg, P GA 
score) at prior post-baseline visits, b aseline strata, and treatment group as covariates, The 
ROUND and MINIMUM options will be utilized to ensure imputed values are non- negative 
integers .  The seed to be used is 20180330.  The results of the 100 analyses will be transformed 
into a normal statistic and combined into a single analysis using PROC MIANALYZE. 
Tapi[INVESTIGATOR_402197] -505-3001  
Dermavant Sciences GmbH.  Clinical Study Protocol – Version 2.0  
Confidential  Page | 64 11. RESPONSIBILITIES  
11.1. Investigator Responsibilities  
11.1.1. Good Clinical Practice  
The Investigator will ensure that this study is conducted in accordance with the principles of the 
“Declaration of Helsinki ” (as amended in Edinburgh, Tokyo, Venice, Hong Kong, and South 
Africa), International Conference on Harmonization (ICH) guidelines, or with the laws and regulations of the country in which the research is conducted, whichever affords the greater protectio n to the study subject .  For studies conducted under a [LOCATION_002] Investigational New 
Drug Application (IND), the Investigator will ensure that the basic principles of “Good Clinical Practice,” as outlined in 2 1 Code of Federal Regulations (CFR) 312, subpart D, “Responsibilities 
of Sponsors and Investigators,” 21 CFR, part 50, 1998, and 21 CFR, part 56, 1998, are adhered 
to.  These standards are consistent with the requirements of the European Community Directive 
2001/20/EC. 
Since this is a “covered” cli nical trial, the Investigator will ensure that 2 1 CFR, Part 54, 1998, is 
adhered to; a “covered” clinical trial is any “study of a drug or device in humans submitted in a 
marketing application or reclassification petition subject  to this part that the appl icant or Food 
and Drug Administration ( FDA ) relies on to establish that the product is effective (including 
studies that show equivalence to an effective product) or that make a significant contribution to the demonstration of safety.” This requires that Investigators and all sub- investigators must 
provide documentation of their financial interest or arrangements with the Sponsor, or 
proprietary interests in the drug being studied.  This documentation must be provided before 
participation of the Investigator and any sub-investigator.  The Investigator and sub-investigator agree to notify the Sponsor of any change reportable interests during the study and for [ADDRESS_506882]/Independent Ethics Committee Approval  
This protocol and any accompanying material to be provided to the subject (such as advertisements, subject  information sheets, or descriptions of the study used to obtain informed 
consent) will be submitted by [CONTACT_191855].  Approval from the IRB or IEC 
must be obtained before starting the study and should be documented in a letter to the 
Investigator specifying the protocol number, protocol version, protocol date, documents 
reviewed, and date on which the committee met and granted the approval. 
Any modifications made to the protocol after receipt of IRB or IEC approval must also be 
submitted to the IRB or IEC for approval before implementation. 
11.1.3. Informed Consent/Assent  
The Investigator is responsible for obtaining written informed consent/assent from each 
individual participating in this study after adequate explanation of the aims, methods, objectives, 
and potential hazards of the study and before undertaking any study- related procedures .  The 
Investigator must utilize an IRB - or IEC -approved consent form for documenting written 
informed consent.  Each informed consent/assent will be appropriately signed and dated by [CONTACT_402266] ’s legally authorized representative and the person obtaining consent. 
Tapi[INVESTIGATOR_402197] -505-3001  
Dermavant Sciences GmbH.  Clinical Study Protocol – Version 2.0  
Confidential  Page | [ADDRESS_506883] s’ anonymity will be strictly maintained and that their 
identities are protected from unauthorized parties .  Only subject  number, date of birth, and an 
identification code (ie , not names) should be recorded on any form or biological sample 
submitted to the Sponsor, IRB or IEC, or laboratory.  The Investigator must keep a screening log 
showing codes, names, and addresses for all subject s screened and for all subject s enrolled in the 
trial. 
The Investigator agrees that all information received from the Sponsor, including but not limited to the Investigator Brochure, this protocol, eCRFs, the investigational new drug, and any other 
study information, remain the sole and exclusive property of the Sponsor during the conduct of the study and thereafter.  This information is not to be disclosed to any third party (except 
employees or agents directly involved in the conduct of the study or as required by [CONTACT_2371]) without 
prior written consent from the Sponsor.  The Investigator further agrees to take all reasonable precautions to prevent the disclosure by [CONTACT_250249]. 
11.1.5. Study Files and Retention of Records  
The Investigator must maintain adequate and accurate records to enable the conduct of the study to be fully documented and the study data to be subsequently verified.  These documents should 
be classified into at least the following 2 categories :  (1) Investigator’s study file, and (2) subject 
clinical source documents.  
The Investigator’s study file will contain the protocol/amendments, eCRF and query forms, IRB or IEC and governmental approval with correspondence, informed consent, drug records, staff 
curriculum vitae and authorization forms, and other appropriate documents and correspondence. 
The required source data should include at least the following information for each subje ct: 
• Subject  identification (name, date of birth, gender) 
• Documentation that subject  meets eligibility criteria, ie , history, physical 
examination, and confirmation of diagnosis (to support inclusion and exclusion 
criteria)  
• Participation in trial (including  trial number)  
• Trial discussed and date of informed consent 
• Dates of all visits  
• Documentation that protocol- specific procedures were performed  
• Results of efficacy parameters, as required by [CONTACT_760] 
• Start and end dates (including dose regimen) of trial medication (preferably drug dispensing and return should be documented as well) 
• Record of all adverse events and other safety parameters (start and end date, and preferably including causality and intensity) 
• Concomitant medication (including start and end dates, dose if relevant; dose changes should be motivated) 
• Date of trial completion and reason for early discontinuation, if applicable 
Tapi[INVESTIGATOR_402197] -505-3001  
Dermavant Sciences GmbH.  Clinical Study Protocol – Version 2.0  
Confidential  Page | [ADDRESS_506884] approval of a m arketing ap plication in an ICH region (ie, [LOCATION_002], Europe, or Japan) 
and until there are no pending or contemplated marketing applications in an ICH region; or, if no 
application is filed or if the application is not approved for such indication, until [ADDRESS_506885] enrolled, an electronic case report form (eCRF) must be completed and signed 
by [CONTACT_137996]- investigator (as appropriate) .  This also applies to records for those 
subject s who fail to complete the study.  If a subject  withdraws from the study, the reason must 
be noted on the eCRF.  If a subject  is withdrawn from the study because of a treatment- limiting 
adverse event, thorough efforts should be made to clearly document the outcome. 
11.1.7. Drug Accountability  
The Investigator or desig nee (ie, pharmacist) is responsible for ensuring adequate accountability 
of all used and unused investigational medicinal product.  This includes acknowledgment of 
receipt of each shipment of study product (quantity and condition), subject  dispensing records, 
and returned or destroyed study product.  Dispensing records will document quantities received from the Sponsor and quantities dispensed to subject s, including lot number, date dispensed, 
subject  identifier number, and the initials of the person dispensing the medication. 
At study initiation, the monitor will evaluate the site’s procedure for investigational medicinal product disposal/destruction in order to ensure that it complies with the Sponsor requirements.  At the end of the study, following final drug inventory reconciliation by [CONTACT_2037], the study 
site will dis pose of and/or destroy all unused investigational medicinal product supplies, 
including empty containers, according to these procedures.  If the site cannot meet the Sponsor’s 
requirements for disposal, arrangements will be made between the site and the Sp onsor or its 
representative for destruction or return of unused investigational medicinal product supplies. 
All drug supplies and associated documentation will be periodically reviewed and verified by [CONTACT_69878]. 
Tapi[INVESTIGATOR_402197] -505-3001  
Dermavant Sciences GmbH.  Clinical Study Protocol – Version 2.0  
Confidential  Page | [ADDRESS_506886] be obtained before 
chan ges can be implemented. 
11.2.2. Study Report and Publications  
A clinical study report will be prepared and provided to the regulatory agency(ies).  The Sponsor 
will ensure that the report meets the standards set out in the ICH Guideline for Structure and 
Content of Clinical Study Reports (ICH E3).  Note that an abbreviated report may be prepared in certain cases.  
After conclusion of the study and without prior written approval from Dermavant Sciences GmbH, Investigators in this study may communicate, orally present, or publish in scientific journals or other scholarly media only after the following conditions have been met: 
• The results of the study in their entirety have been publicly disclosed by [CONTACT_402267], in an abstract, manuscript, or presentation 
form; OR 
• The study has been completed at all study sites for at least 5 years.  
No such communication, presentation, or publication will include Dermavant Sciences GmbH confidential information (see Section  11.1.4).  
The Investigator will submit any proposed publication or presentation along with the respective scientific journal or presentation forum at least [ADDRESS_506887] to delete 
references to its confidential information (other than the study results) in any paper or presentation and agrees to withhold publication or presentation for an additional 60 days in order to obtain patent protection if deemed necessary. 
11.2.3. Posting of Information on Publicly Available Clinical Trial Registers  
Study information from this protocol will be posted on publicly available clinic al trial registers 
before enrollment of subjects begins.  Results will be posted as required. 
Tapi[INVESTIGATOR_402197] -505-3001  
Dermavant Sciences GmbH.  Clinical Study Protocol – Version 2.0  
Confidential  Page | 68 11.3. Joint Investigator/Sponsor Responsibilities  
11.3.1. Access to Information for Monitoring  
In accordance with ICH Good Clinical Practice guidelines, the study monitor must have direct 
access to the Investigator’s source documentation in order to verify the data recorded in the 
eCRFs for consistency. 
The monitor is responsible for routine review of the eCRFs at regular intervals throughout the 
study to verify adherence to the protocol and the completeness, consistency, and accuracy of the 
data being entered on them.  The monitor should have access to any subject records needed to verify the entries on the e CRFs .  The Investigator agrees to cooperate with the monitor to ensure 
that any problems detected in the course of these monitoring visits are resolved. 
11.3.2. Access to Information for Auditing or Inspections  
To ensure compliance with Good Clinical Practices and all applicable regulatory requirements, 
Dermavant Sciences  GmbH may co nduct a quality assurance audit. 
Authorized representatives of Dermavant Sciences  GmbH, a regulatory authority, an 
Independent Ethics Committee or an Institutional Review Board may visit the site to perform audits or inspections, including source data veri fication .  The purpose of a Dermavant Sciences  
GmbH audit or inspection is to systematically and independently examine all study- related 
activities and documents to determine whether these activities were conducted, and data were recorded, analyzed, and accurately reported according to the protocol, Good Clinical Practice 
guidelines of the International Conference on Harmonization, and any applicable regulatory 
requirements .  The investigator should contact [CONTACT_402268] b y a regulatory agency about an inspection. 
Representatives of regulatory authorities or of the Sponsor may conduct inspections or audits of the clinical study .  If the Investigator is notified of an inspection by a regulatory authority the 
Investigator agrees to notify the Sponsor M edical Monitor immediately .  The Investigator agrees 
to provide to representatives of a regulatory agency or the Sponsor access to records, facilities, and personnel for the effective conduct of any inspection or audit. 
11.3.3. Study Discontinuation  
The Sponsor reserves the right to terminate the study at any time.  Should this be necessary, the 
Sponsor will arrange discontinuation procedures and notify the appropriate regulatory 
authority(ies), IRBs, and IECs .  In terminating th e study, the Sponsor and the Investigator will 
assure that adequate consideration is given to the protection of the subject s’ interests.  
Tapi[INVESTIGATOR_402197] -505-3001  
Dermavant Sciences GmbH.  Clinical Study Protocol – Version 2.0  
Confidential  Page | 69 12. REFERENCES 
Basra MK, Salek MS, Camilleri L, Sturkey R, Finlay AY Dermatology.  Determining the 
minimal clinically impor tant difference and responsiveness of the Dermatology Life Quality 
Index (DLQI) :  further data.2015;230(1):27-33. 
Cappon GD and Hurtt ME.  Developmental toxicity of the kidney.  In:  Kapp RW and Yyl L, 
editors.  Reproductive Toxicology, Tar get Organ Series , 3rd edition.  [LOCATION_001]:Informa 
Healthcare, 2010:193-204. 
Frazier KS and Seely JC .  Urinary system.  In:  Sahota PS, Popp JA, Hardisty JF and Gopi[INVESTIGATOR_92063] 
C, editors.  Toxicologic Pathology:  Nonclinical Safety Assessment .  CRC Press, 2013:421-84. 
Lebwohl M, Swensen AR, Nyirady J, Kim E, Gwaltney CJ, Strober BE.  The Psoriasis Symptom 
Diary :  development and content validity of a novel patient-reported outcome instrument.  Int J 
Dermatol .  2014;53:714-722. 
Maruish , ME, editor.  User’s manual for the SF -36v2 health survey.  Edition 3.  Quality Metric 
Inc.  2011. 
Mason AR, Mason J, Cork M, Dooley G, Hancock H.  Topi[INVESTIGATOR_402233].  Cochrane Database of Systematic Reviews .  2013;(3):CD005028. doi :  
10.1002/14651858.CD005028.pub3. 
Parisi R, Symmons DPM, Griffiths CEM, Ashcroft DM.  Global epi[INVESTIGATOR_82701]:  a 
systematic review of incidence and prevalence.  J Invest Dermatol .  2012;133:377-385. 
Strober BE, Yirady J, Mallya UG, Guettner A, Papavassilis C, Gottlieb AB, et al. Item-level 
psychometric properties for a new patient- reported Psoriasis Symptom Diary .  Value Health 
2013;16(6):1014-1022. 
Strober B, Zhao Y, Tran MH, Gnanasakthy A, Nyirady J, Papavassilis C, et al. Psychometric 
validation of the Psoriasis Symptom Diary using Phase III study data from patients with chronic 
plaque psoriasis.  Int J Dermatol.  2016:55(3):e147-155. 
Zoetis T and Hurtt ME.  Species comparison of anatomical and functional renal development.  Birth Defects Research Part B .  2003;68:111-120. 
Tapi[INVESTIGATOR_402197] -505-3001  
Dermavant Sciences GmbH.  Clinical Study Protocol – Version 2.0  
Confidential  Page | 70 13. APPENDICES  
APPENDIX  1. HOSPI[INVESTIGATOR_402234] 
(HADS) 
 
Tapi[INVESTIGATOR_402197] -505-3001  
Dermavant Sciences GmbH.  Clinical Study Protocol – Version 2.0  
Confidential  Page | 71     FOLD HERE  Hospi[INVESTIGATOR_58900] (HADS)  
Name:  ________________________________ _______________________   Date:  _______________  
Clinicians are aware that emotions play an important part in most illnesses. If your clinician knows about 
these feelings he or she will be able to help you more.  
This questio nnaire is designed to help your clinician to know how you feel. Read each item below and 
underline the reply which comes closest to how you have been feeling in the past week. Ignore the 
numbers printed at the edge of the questionnaire.  
Don’t take too long  over your replies, your immediate reaction to each item will probably be more 
accurate than a long, thought -out response.  FOLD HERE  
Please make sure you have answered  all the questions . 
A D 
TOTAL  
HADS c opyright © R P Snaith a nd A S Zigmond, 1983, 1992, [ADDRESS_506888] fo rm items o riginally p ublished i n Acta Psychiatrica Scandinavica, 67, 361–70,  
c
opyright © Munksgaard International P ublishers L td, C openhagen, [ADDRESS_506889] obtaining permission from the publisher   
E-mail: permissions@gl-a ssessment co uk  
All rights r eserved i ncluding t ranslations  A D 
I feel tense or "wound up"  
[ADDRESS_506890] of the time  
2 A lot of the time  
1 From time to time, occasiona lly 
0 Never  
I enjoy the things I used to enjoy  
0 Definitely  
1 Not quite so much  
2 Only a little  
3 Hardly at all  
I get a sort of frightened feeling as if 
something awful is about to happen  
3 Very definitely and fairly badly 
2 Yes, but not too badly  
1 Sometimes , but it doesn’t worry me  
[ADDRESS_506891] of the time  
I can sit at ease and feel relaxed  
0 Always  
1 Usually  
2 Not often  
3 Never  A D 
I feel as if I am slowed down  
Nearly all the time  3 
Very often  2 
Sometimes  1 
Never  0 
I get a sort of anxious  feeling like  
"butterflies" in the stomach  
Never  [ADDRESS_506892] in my appearance  
Definitely  3 
Often I don't take as much  care as I should  2 
Sometimes I don't take as much  care as I should  [ADDRESS_506893]  0 
Somewhat less than I used to  1 
Much less than I used to  2 
Rarely  3 
I get sudden feelings of panic  
Very often  3 
Often 2 
Not very often  1 
Never  0 
I can enjoy a good book, radio  or  
television program  
Often  0 
Sometimes  1 
Not often  2 
Very seldom  3 
Tapi[INVESTIGATOR_402197] -505-3001  
Dermavant Sciences GmbH.  Clinical Study Protocol – Version 2.0  
Confidential  Page | 72 APPENDIX  2. PHYSICIAN GLOBAL ASS ESSMENT  (PGA)  
Each assessment should be made as a visual “average” of the severity of all treated areas at the 
time of the assessment .  Following the Baseline visit, assessments will be made without 
reference to Baseline state or any other previous scores. 
Scoring should not be influenced by [CONTACT_191859], participant symptoms, or impact on 
participant’s quality of life .   
Score/Grade  Description  
0 Clear  No signs of psoriasis;  postinflammatory hyperpi[INVESTIGATOR_22765]  
[ADDRESS_506894] clear  No thickening; normal to pi[INVESTIGATOR_22766]; no to minimal focal scaling 
[ADDRESS_506895] detectable to mild thickening; pi[INVESTIGATOR_22767]; predominantly fine scaling  
3 Moderate  Clearly distinguishable to moderate thickening; dull to bright red, clearly distinguishable 
erythema; moderate scaling  
[ADDRESS_506896] edges; bright to deep dark red coloration; severe/coarse 
scaling covering almost all or all lesions  
Langley RGB, Feldman SR, Nyirady J, van de Kerkhof P, Papavassilis C .  The 5 -point Investigator’s Global 
Assessment (IGA) Scale:  A mo dified tool for evaluating plaque psoriasis severity in clinical trials .  J Dermatolog 
Treat .  2015;26(1):23- 31. 
Ta pi [INVESTIGATOR_402235]  D M V T -[ADDRESS_506897] u d y Pr ot oc ol – Versi o n 2. 0  
C o nfi de ntial  Pa ge | 7 5  A P P E N DI X  4.  D E R M A T O L O G Y LI F E Q U A LI T Y I N D E X ( D L QI) A G E S 
[ADDRESS_506898] wee k, h o w itc h y , s ore , p ai nf ul  or sti n gi n g  h as y o ur s ki n b ee n ?  Ver y m u c h  
A l ot  
A little  
N ot at all   
 
 
  
2.   O v er t h e last wee k, h o w e m b a rr asse d  or self c o nsci o us  h a v e y o u b ee n b eca use 
of y o ur s ki n ?  Ver y m u c h  
A l ot  
A little  
N ot at all   
 
 
  
3.   O v er t h e last wee k, h o w m u c h h as y o ur s ki n i nterfere d wit h y o u g oi n g 
s h o p pi n g  or l o o ki n g after y o ur h o m e  or y a r d ?  Ver y m u c h  
A l ot  
A little  
N ot at all   
 
 
  
 
 
   N ot rele v a nt   
4.   O v er t h e last wee k, h o w m u c h h as y o ur s ki n i nfl u e n ce d t h e cl ot hes  y o u 
wear?  Ver y m u c h  
A l ot  
A little  
N ot at all   
 
 
  
 
 
   N ot rele v a nt   
5.   O v er t h e last wee k, h o w m u c h h as y o ur s ki n affecte d a n y s o ci al  or leis ure  
acti vities?        Ver y m u c h  
A l ot  
A little  
N ot at all   
 
 
  
 
 
   N ot rele v a nt   
6.   O v er t h e last wee k, h o w m u c h h as y o ur s ki n ma d e it diffic ult f or y o u t o d o 
a n y s p o rt ? 
 Ver y m u c h  
A l ot  
A little  
N ot at all   
 
 
  
 
 
   N ot rele v a nt   
7.   O v er t h e last wee k, h as y o ur s ki n pre v e nte d y o u fr o m w o r ki n g  or st u d yi n g ? Yes  
N o   
  
   N ot rele v a nt   
If " N o", o v er t h e last wee k h o w m u c h h as y o ur s ki n b ee n a pr o ble m at w o r k  or 
st u d yi n g ? A l ot  
A little  
N ot at all   
 
  
 
8.   O v er t h e last wee k, h o w m u c h h as y o ur s ki n create d pr o ble ms wit h y o ur 
p a rt ner  or a n y of y o ur cl ose frie n ds or rel ati v es ?     Ver y m u c h  
A l ot  
A little  
N ot at all   
 
 
  
 
 
   N ot rele v a nt   
9.   O v er t h e last wee k, h o w m u c h h as y o ur s ki n ca use d a n y se x u al diffic ulties ?  Ver y m u c h  
A l ot  
A little  
N ot at all   
 
 
  
 
 
   N ot rele v a nt   
[ADDRESS_506899] wee k, h o w m u c h of a pr o ble m h as t h e tre at m e nt  f or y o ur s ki n 
b ee n, f or e x a m ple b y ma ki n g y o ur h o me mess y, or b y ta ki n g u p ti me?  Ver y m u c h  
A l ot  
A little  
N ot at all   
 
 
  
 
 
   N ot rele v a nt   
© A Y Fi nla y, G K K ha n, A pril [ADDRESS_506900] n ot be c o pie d wit h o ut t he per missi o n of 
t he a ut h ors.  
 
Tapi[INVESTIGATOR_402197] -505-3001  
Dermavant Sciences GmbH.  Clinical Study Protocol – Version 2.0  
Confidential  Page | 76 APPENDIX  5. 36−ITEM SHORT FORM SURVEY ; VERSION 1.0 (SF-36) 
36-Item Short Form Survey Instrument (SF -36)  
 
RAND 36 -Item Health Survey 1.0 Questionnaire Items  
 
Choose one option for each questionnaire item. 
 
1. In general, would you say your health is: 
o 1 – Excellent  
o 2 – Very good 
o 3 – Good 
o 4 – Fair  
o 5 – Poor 
 
2. Compared to one year ago, how would you rate your health in general now ? 
o 1 – Much better now than one year ago 
o 2 – Somewhat better now than one year ago 
o 3 – About the same 
o 4 – Somewhat worse now than one year ago 
o 5 – Much worse now than one year ago 
  
Tapi[INVESTIGATOR_402197] -505-3001  
Dermavant Sciences GmbH.  Clinical Study Protocol – Version 2.0  
Confidential  Page | 77 The following items are about activities you might do during  a typi[INVESTIGATOR_5707]. Does your health now 
limit you  in these activities? If so, how much? 
 Yes, 
limited a lot Yes, limited a little No, not limited at all 
3. Vigorous activities , such as running, lifting heavy objects, 
participating in strenuous sports 
o [ADDRESS_506901] you had any of the following problems with your work or other regular 
daily activities as a result of your physical health ? 
  Yes No 
13. Cut down the amount of time  you spent on work or other activities  o 1 o 2 
14. Accomplished less  than you would like   o 1 o 2 
15. Were limited in the kind  of work or other activities   o 1 o 2 
16. Had difficulty  performing the work or other activities (for example, it took 
extra effort)  o 1 o 2 
  
Tapi[INVESTIGATOR_402197] -505-3001  
Dermavant Sciences GmbH.  Clinical Study Protocol – Version 2.0  
Confidential  Page | [ADDRESS_506902] you had any of the following problems with your work or other regular 
daily activities as a result of any emotional problems  (such as feeling depressed or anxious)? 
   
Yes  No 
17. Cut down the amount of time  you spent on work or other activities   o 1 o 2 
18. Accomplished less  than you would like   o 1 o 2 
19. Didn’t do work or other activities as carefully  as usual   o [ADDRESS_506903] 4 weeks , to what extent has your physical health or emotional problems interfered 
with your normal social activities with family, friends, neighbors, or groups? 
 
o 1 – Not at all 
o 2 – Slightly  
o 3 – Moderately  
o 4 – Quite a bit 
o [ADDRESS_506904] 4 weeks ? 
o 1 – None 
o 2 – Very mild  
o 3 – Mild  
o 4 – Moderate  
o 5 – Severe  
o 6 – Very severe  
 
Tapi[INVESTIGATOR_402197] -505-3001  
Dermavant Sciences GmbH.  Clinical Study Protocol – Version 2.0  
Confidential  Page | [ADDRESS_506905] 4 weeks , how much did pain  interfere with your normal work (including both 
work outside the home and housework)? 
 
o 1 – Not at all 
o 2 – A little bit  
o 3 – Moderately  
o 4 – Quite a bit 
o [ADDRESS_506906] 4 weeks…  
 All of 
the 
time Most of 
the time  A good 
bit of the time Some 
of the time A little 
of the time None of 
the time  
23. Did you feel full of pep?  o [ADDRESS_506907] you been a very nervous 
person? o [ADDRESS_506908] you felt so down in the dumps that nothing could cheer you up? o [ADDRESS_506909] you felt calm and peaceful?  o [ADDRESS_506910] a lot of energy? o [ADDRESS_506911] you felt downhearted and 
blue? o 1 o 2 o 3 o 4 o 5 o 6 
29. Did you feel worn out?  o [ADDRESS_506912] you been a happy person? o 1 o 2 o 3 o 4 o 5 o 6 
31. Did you feel tired?  
 o 1 o 2 o 3 o 4 o 5 o 6 
Tapi[INVESTIGATOR_402197] -505-3001  
Dermavant Sciences GmbH.  Clinical Study Protocol – Version 2.0  
Confidential  Page | [ADDRESS_506913] 4 weeks , how much of the time has your physical health or emotional problems  
interfered with your social activities (like visiting with friends, relatives, etc.)?  
 
o 1 – All of the time  
o 2 – Most of the time  
o 3 – Some of the time  
o 4 – A little of the time  
o 5 – None of the time 
 
 
How TRUE or FALSE is each  of the following statements for you. 
 Definitely 
true Mostly 
true Don’t 
know Mostly 
false  Definitely 
false  
33. I seem to get sick a little easier than other 
people o [ADDRESS_506914] my health to get worse  o 1 o 2 o 3 o 4 o 5 
36. My health is excellent  o 1 o 2 o 3 o 4 o 5 
 
RAND® is a registered trademark. Copyright © 1994 -2018 RAND Corporation.   
 
 
  
 
Tapi[INVESTIGATOR_402197] -505-3001  
Dermavant Sciences GmbH.  Clinical Study Protocol – Version 2.0  
Confidential  Page | 81 APPENDIX  6. PSORIASIS SYMPTOM DI ARY  (PSD)  
 

Tapi[INVESTIGATOR_402197] -505-3001  
Dermavant Sciences GmbH.  Clinical Study Protocol – Version 2.0  
Confidential  Page | 82  
 
 
 
 
 

Tapi[INVESTIGATOR_402197] -505-3001  
Dermavant Sciences GmbH.  Clinical Study Protocol – Version 2.0  
Confidential  Page | 83 APPENDIX  7. PEAK PRURITUS -NUMERIC RATING SCALE  
(PRURITUS -NRS)  
Peak Pruritus -NRS is a scale used to quickly assess itch/pruritus severity over a 24-hour period.  
The subject will utilize the scale shown daily to assess peak pruritus. 
 

Tapi[INVESTIGATOR_402197] -505-3001  
Dermavant Sciences GmbH.  Clinical Study Protocol – Version 2.0  
Confidential  Page | 84 APPENDIX  8. LOCAL TOLERABILITY SCALE  ASSESSMENT  
At each specified study visit, the I nvestigator (or qualified  evaluator) will assess the  presence 
and overall degree of irritation at the application sites, according to the 5- point scale below .  The 
score will ideally represent an “average ” across all application sites .  To the fullest extent 
possible, the same investigator (or designated evaluator) will perform all tolerability assessments 
for an individual participant throughout the study.   
If the participant is applying study treatment to “sensitive areas” (eg, genitals, face, neck, and 
skin folds), then also assess the degree of irritation for these areas.  
Local Tolerability – Dryness, Erythema, and Peeling  
Score Severity  Description  
0 No irritation  No evidence of local irritation/intolerance  
1 Mild  Minimal erythema and/or edema, slight glazed appearance  
2 Moderate  Definite erythema and/or edema with peeling and/or cracking but does not 
require treatment modification  
3 Severe Erythema, edema glazing with fissures, few vesicles or papules  
4 Very Severe  Strong reaction spreading beyond the treated area, bullous reaction, 
erosions  
At each specified study visit, the participant will use 5 -point tolerability scale presented in the 
table below to assess the presence and degree of burning/stinging and itching at the treatment 
areas .  The score w ill ideally represent an “average” across all application sites.  
Local Tolerability – Burning/Stinging and Itching  
Score Severity  Description  
0 None  Normal, no discomfort  
1 Slight An awareness, but no discomfort and no intervention required 
2 Mild  A noticeable discomfort that causes intermittent awareness  
3 Moderate  A noticeable discomfort that causes intermittent awareness and interferes 
occasionally  with normal daily activities  
4 Strong/Severe  A definite continuous discomfort that interferes with normal daily activities 
 
  
Tapi[INVESTIGATOR_402197] -505-3001  
Dermavant Sciences GmbH.  Clinical Study Protocol – Version 2.0  
Confidential  Page | 85 APPENDIX 9: PROTOCOL AMENDMENT S UMMARY OF CHANGES  
The protocol has been updated with the following changes.  Edits to the protocol are shown in 
bold . 
Table 1. Schedule of Assessment  
Urinalysis and clinical laboratory tests added to the Early Termination visit.  
Section 1.1, page 23. Background Information 
Correction made to reflect language in study report; “ contact [CONTACT_8748] ” changed to “ dermatitis 
contact .” 
The most frequently reported (1% to  6% of 235 subjects) dermatological adverse events (AEs), 
regardless of causality, were application site discoloration/hyperpi[INVESTIGATOR_371], application site 
dermatitis, papular rash, pruritus, contact [CONTACT_191861] , folliculitis, erythema, and skin 
burning sensation.   
Section [IP_ADDRESS].  Clarification on study design added; 
In the open -label PK Study 201851 with BID dosing  of Formulation F of tapi[INVESTIGATOR_191753] 
(n=11) , 1% and 2%, headache was the most frequently reported during the study (reported for 
100% and 60% of subjects at the 1% and 2% doses, respectively). 
Section 3.1 Overall Design 
Clarified wording around time of dosing each day and protocol violations which is further 
addressed in Section 5.1.5 (Administration of Study Drug) 
Section 4.3. Exclusion criteria #3b and #16 
Corrected inconsistencies between 2 criteria in systemic infections requiring treatment prior to 
enrollment as 4 weeks  before the baseline visit.  
Section 4.3. Exclusion criterion #[ADDRESS_506915] with stable non- alcoholic fatty 
liver disease without evidence of active inflammation or cirrhosis is  eligible to enroll.  
Section 4.3. Exclusion criterion #9 and Section 5.6.2 Prohibited Medications and Nondrug 
Therapi[INVESTIGATOR_402236] a daily dose for the oral Vitamin D3 and analogs exclusion and added topi[INVESTIGATOR_402237] 4.3. Exclusion criterion #15 
Clarified exemptions for current or history of cancer to “adequately treated  skin basal cell 
carcinoma, squamous cell carcinoma or carcinoma in situ of the cervix  (surgical excision or 
electrodessication and curettage) .” 
Section 4.5 Screening / Baseline Failures  and Section 7.1. Visit 1; Screening P eriod  
Revised wording regarding repeat lab and procedures based on the Investigator’ s discretion with 
consultation of the Medical Monitor on an “as needed” basis. 
Section 5.1.5.  Administration of Study Drug 
Tapi[INVESTIGATOR_402197] -505-3001  
Dermavant Sciences GmbH.  Clinical Study Protocol – Version 2.0  
Confidential  Page | 86 Added clarification wording around missed doses and protocol deviations: “ If a subject misses a 
daily dose, it will be recorded as a protocol deviation. The subject should continue dosing 
the next day and should not apply more than once daily to make up for the missed dose on the previous day.” 
Section [IP_ADDRESS].  Peak Pruritus- Numeric rating Scale  
Added clarification wording: “ On clinic visit days, the Peak -Pruritis NRS will be assessed in 
the clinic and not recorded in the diary .”   
Section 7.2, page 48. 7.2. Visit 2; Baseline (Day 1) 
Removed the collection of a PK sample to be consistent with Table 1, Schedule of Assessments 
Section 7.5 Assessments  
Addition of additional safety assessments.  Urinalysis  and c linical laboratory tests added at 
Early Termination visit.  
Section 8.1.1. Definition of Adverse Events 
To avoid confusion, the wording that defines local adverse events has been edited since “evaluation of local tolerability” is being assessed with a specific scale (Appendix 8).  
Appendix 1. HOSPI[INVESTIGATOR_328650] (HADS)  
Revised  HADS  example added . 
Appendix 3, page 75. CALCULATION of BSA and PASI 
Clarification of body surface area calculation and correction in table for calculation of PASI; 
score of 0  changed from 1% to 0% skin covered with psoriasis and score of 1 changed from 1 - 
<10% to <10% consistent with published paper (Feldman Feldman SR, Krueger GG. Psoriasis assessment tools in clinical trials. Ann Rheum Dis.2005;64 (suppl II):ii65-ii68.) 
 Percentage of skin covered  with psoriasis for each of the 4  areas  
Affected  0% < 10% 10 - < 30% 30 - < 50% 50 - < 70% 70 - < 90% ≥ 90% 
Score 0 1 2 3 4 5 6 
Appendix 8, page 85. LOCAL TOLERABILITY SCALE ASSESSMENT 
Removed unnecessary footnote under the Local Tolerability – Dryness, Erythema, and Peeling 
table.  
 